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Hydrogen sulfide (H2S) is an endogenous inflammatory mediator produced by the activity of 
cystathionine γ–lyase (CSE) in mammals. Macrophages are a key element of the immune 
system and play a crucial role in inflammation. To determine the role of H2S and macrophages 
in inflammation, the expression of CSE in the murine macrophage cell line and human primary 
macrophages was investigated. The results showed that H2S is produced by the activity of CSE 
in macrophages. Acute pancreatitis is an inflammatory disorder in the pancreas which develops 
a cascade of immunological events and results in the activation of inflammatory cells including 
macrophages. After confirming that H2S is produced by the activity of CSE in macrophages 
the primary aim was to demonstrate the importance of hydrogen sulfide in the activation of 
macrophages by inhibiting CSE expression in macrophages during inflammation. 
Previous studies using pharmacological inhibition of CSE with (DL-propargylglycine) PAG 
produced conflicting results that may be due to the lack of specificity of this pharmacological 
agent. To overcome this problem, specific small interfering RNA (siRNA) molecules were 
used to silence CSE and inhibit the production of H2S by this enzyme in both in vitro and in 
vivo experiments. SiRNA treatment reduced the levels of CSE mRNA and protein in LPS-
activated macrophages compared with controls and non-transfected cells. Furthermore, the 
levels of pro-inflammatory cytokines by LPS activated macrophages were significantly lower 
in siRNA transfected cells compared to untransfected controls. For example, increased levels 
of TNF-α (ng/ml) were observed by LPS-treated cells (11.22 ± 3.340SD) compared to control 
cells (0.03165 ± 0.00998SD) while there was a significant reduction (One-way ANOVA, 
p<0.01) in the levels of TNF-α in the siRNA transfected cells (7.782 ± 2.289SD). However, 
the production levels of NO by the transfected cells was higher, suggesting that CSE activity 
had an inhibitory effect on NO production. These findings suggest that the CSE enzyme has a 
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crucial role in the activation of macrophages and its activity has an inhibitory effect on NO 
production by these cells.  
The mechanism by which H2S acts as an inflammatory mediator in LPS-induced macrophages 
(transfected with anti CSE siRNA) was investigated further. LPS-induced activation of 
transcription factor nuclear factor-κB (NF-κB) was reduced compared with untransfected cells 
and phosphorylation and activation of mitogen-activated protein kinase (ERK) 1/2 increased 
in LPS-induced macrophages. Phosphorylation of ERK in LPS-induced RAW 264.7 cells 
reached a peak at 30 minutes after activation. Silencing the CSE gene by siRNA reduced 
phosphorylation and activation of ERK1/2 in LPS-induced RAW 264.7 cells. These findings 
suggest that siRNA reduces the inflammatory effects of CSE through the ERK-NF-κB 
signalling pathway. To determine the role of common signalling pathway in biosynthesis of 
CSE in human primary macrophages, specific inhibitors were used to block NF-κB, ERK, p38 
and JNK. Inhibition of NF-κB, ERK and JNK resulted in reduced levels of CSE expression in 
these cells but inhibition of p38 did not reduce the CSE expression in macrophages.  
To investigate the role of CSE expressed by macrophages, an in vivo mouse model of caerulein-
induced acute pancreatitis was employed. SiRNA was injected into the tail vein to transfect 
blood monocytes. Higher levels of the pro-inflammatory cytokines TNF-α, IL-6, IL-1β and 
MIP-2 were found in the pancreas and the lung, as well as increased activity of pancreatic and 
lung MPO and plasma amylase levels were observed following caerulein-induced acute 
pancreatitis in mice. The siRNA treatment attenuated inflammation in the pancreas and lungs 
of mice following acute pancreatitis, as shown by MPO activity, plasma amylase activity and 
histology. Caerulein treatment increased pancreatic MPO activity (fold increase over saline 
group) (16.95 ± 3.22SD), but administration of siRNA before caerulein treatment reduced 
MPO activity significantly (3.97 ± 2.29SD) (One-way ANOVA, p<0.0001). There was also 
significantly reduced lung MPO activity following administration of siRNA. Caerulein 
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treatment increased lung MPO activity (fold increased over saline group) (3.71 ± 0.84SD) 
while siRNA administration prior to caerulein treatment reduced lung MPO activity 
significantly (0.84 ± 0.38SD) (One-way ANOVA, p<0.0001). SiRNA treatment also reduced 
levels of pro-inflammatory mediators including IL-6, MCP-1, TNF-α, and IL-1β in the 
pancreas and the lung. These results were supported by histological experiments of the 
pancreas and the lung which demonstrated reduced infiltration of inflammatory leukocytes 
following silencing of CSE expression in macrophages compared to the mice without siRNA 
treatment. These findings indicate a crucial pro-inflammatory role for H2S synthesized by CSE 
in macrophages in acute pancreatitis and suggest a therapeutic role for siRNA to specifically 
silence CSE. The results from this thesis showed that CSE silencing with siRNA reduced 
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Acute pancreatitis is an inflammatory disorder of the pancreas characterised by interstitial 
oedema, inflammation and acinar cell necrosis. Distant organ damage such as lung injury is 
associated with acute pancreatitis. It is caused mainly by excessive alcohol consumption and 
gallstones. H2S is an inflammatory mediator produced endogenously in mammalian from L-
cysteine mainly by the activity of two enzymes, cystathionine-γ-lyase (CSE) and cystathionine-
β-synthase (CBS) [1]. A large number of studies have described a key role for H2S in 
inflammatory disorders such as acute pancreatitis.  Inhibition of H2S production by chemical 
inhibitor to inhibit CSE enzyme activity, has resulted in attenuation of acute pancreatitis and 
associated lung injury, suggesting a pro-inflammatory role for H2S in acute pancreatitis [2]. 
Macrophages play a crucial role in inflammation and acute pancreatitis. Inhibition of migration 
of these inflammatory cells by blockade of monocyte chemoattractant protein 1 (MCP-1) has 
resulted in a reduction of disease severity in acute pancreatitis [3]. This thesis will explore the 




Inflammation is a protective process which is initiated by the body in response to tissue injury 
and infection. Inflammatory response leads to the production of inflammatory cytokines and 
chemokines such as tumour necrosis factor alpha (TNF-α), interleukin-1 (IL-1), interleukin-6 
(IL-6), chemokine (C-C motif) ligand 2 (CCL-2), chemokine (C-X-C motif) ligand 8 (CXCL-
8), released by host immune cells. The systemic inflammatory response syndrome (SIRS) and 
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severe tissue damage are caused by excessive production of cytokines [4, 5]. SIRS represents 
a coordinated set of physiological actions affecting the whole body, in response to an insult 
such as infection, pancreatitis, injury, burns or trauma that may progress multiple organ 
dysfunction (MOD) and death [6, 7].  
The sepsis cascade that may  potentially result in MOD and death  has been  reviewed by Balk, 
2014 [8]. The first stage is a local pro-inflammatory response to any injury or infection that is 
initially designed to limit the insult and benefit the host. This may be followed by a second 
stage which is the compensatory anti-inflammatory response (CARS). The purpose of CARS 
is to maintain a balance between pro-inflammatory and anti-inflammatory responses in the 
body. A strong SIRS response may dominent the CARS response and lead to the third stage 
characterised by endothelial dysfunction, increased microvascular permeability and activation 
of the coagulation system. An excessive CARS may result in the fourth stage and cause 
immunosuppression which could increase susceptibility to secondary infection. The fifth stage 
is manifested by MOD and has been recognised as an imbalance between CARS and SIRS that 
results in dysregulation of the immune response. The recognition of the importance of the initial 
the pro-inflammatory response in the pathogenesis of MOD has led to intensive efforts to 
understand and modulate the inflammatory cascade. 
 
1.1.1 Acute pancreatitis 
The pancreas has capability in synthesising protein and includes both exocrine and endocrine 
glands. Most of this capacity of the pancreas is dedicated to digestive enzyme synthesis [9, 10]. 
The exocrine portion of the pancreas consists of acinar cells and ductal cells and make up 95% 
of the pancreatic mass. The secreted digestive enzymes, synthesized in acinar cells, are 
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transported into duodenum via the pancreatic duct. Islet cells make up a small proportion of 
the pancreas and secret insulin, glucagon and pancreatic polypeptide into the blood [11].  
Acinar cells contain lysosomes which are involved in intracellular and extracellular digestion, 
and zymogen containing proenzymes, such as trypsinogen that normally remain inactive [12]. 
Digestive enzymes are produced in the rough endoplasmic reticulum and are secreted through 
the apical surface by exocytosis. Abnormal activation of trypsin in the pancreas is blocked by 
secretory trypsin inhibitor. Furthermore, any leakage of trypsin into the blood will be 
inactivated by the endogenous trypsin inhibitors α1-antitrypsin and α2-macroglobulin [13]. 
Extreme stimulation of exocrine pancreas can cause reflux of pancreatic secretions, obstruction 
of the pancreatic duct, and inflammation and lead to acute pancreatitis.  
Pathophysiological events that result in necrosis of pancreatic tissue are initiated in the acinar 
cell (Figure 1-3) [14-16]. Apical secretion of pancreatic enzymes is blocked and are activated 
within cytoplasmic vesicles. There is misdirected endocytic processing and activation of 
trypsinogen within the acinar cells [15, 17]. A similar study reported by Grady et al (1998) 
showed that zymogen activation can happen in acinar cells and cause injury in these cells. 
Acinar cell injury can lead to the activation and retention of this enzyme, in the acinar cells, 
which activate autodigestion and acute pancreatitis. This conditions have the characteristic 
features such as edema, vascular damage, haemorrhage and necrosis [18, 19]. Acute 
pancreatitis may cause an overwhelming inflammatory response and induce damage to other 
organs, such as the lung, kidney and liver which can result in organ failure and even death [20-
22].   
Serine protease inhibitors such as pancreatic secretory trypsin inhibitor and protease-activated 
receptors-2 protect against prematurely activated trypsinogen [23]. These defences are 
overcome by the amount of trypsin activation. Activation of trypsin leads to tissue damage and 
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the release of more enzymes from injured cells and cause a vicious cycle. Local production of 
ROS and cytokines up-regulation by macrophages and acinar cells are stimulated by trypsin 
[24, 25]. Injured acinar cells are reported to release chemokines which play a key role in 
leukocyte chemoattraction and migration [26]. In addition to zymogen activation, NF-κB 
activation is reported as a key factor in the development of acute pancreatitis. However, their 
independent function is however controversial [27]. NF-kB activation is shown to be in 
association with serum amylase, ROS levels and pancreatic tissue damage in acute pancreatitis. 
Inhibition of NF-kB was shown to ameliorate inflammation in acute pancreatitis and severity 




Figure 1-1. Acinar cell function in acute pancreatitis. In normal acinar cells, zymogen granules are secreted from 
apical poles of acinar cells but in acute pancreatitis, apical poles are blocked and proteases are activated in acinar 
cells, therefore digestive enzymes can access the interstitial space. Under physiological conditions, paracellular 
barriers are tight and block secretion of enzymes from the lumen to the interstitum while in acute pancreatitis, 
dysfunction of tight paracellular barriers results in the reflux of contents from the lumen into the interstitum. 




The Atlanta classification of acute pancreatitis was introduced as a universally applicable 
classification system for acute pancreatitis and has been used by physicians and radiologists 
since 1992 [29]. Recently, the Atlanta classification of acute pancreatitis has been revised and 
now includes two phases of early and late of acute pancreatitis [30]. Severity of acute 
pancreatitis is classified into three levels mild, moderately severe, and severe. Mild acute 
pancreatitis is not accompanied with organ failure and local or systemic complications. 
Moderately severe acute pancreatitis defined by transient organ failure, local complications, 
and exacerbation of coexistent disease. Severe acute pancreatitis is accompanied with the 
presence of persistent organ failure [30, 31].  
Inflammation is a critical process for the pathogenesis of acute pancreatitis. Increased 
pancreatic mRNA levels of Il-1β, IL-6 and TNF-α have been measured in a mouse model of 
acute pancreatitis which confirms an early inflammation occurs in pancreas [32]. The degree 
of cytokine elevation was correlated with disease severity and overall morbidity from 
pancreatitis. Activation of NF-κB which initiate inflammatory response is also observed with 
the development of acute pancreatitis [33, 34] 
 
1.1.2 Aetiology of acute pancreatitis  
Gallstones (38%) and alcohol abuse (36%) are the leading causes to acute pancreatitis in 
developed countries [35]. Gallstones obstruct the bile and pancreatic ducts and induce 
pancreatitis by increasing duct pressure resulting in activation of digestive enzymes [36]. 
Alcohol consumption is considered to be the second most frequent cause of acute pancreatitis. 
The mechanism of induction of acute pancreatitis by gallstones and alcohol differ [37], and 
may lead to differences in clinical severity and complications of acute pancreatitis. Cellular 
injury from a toxic-metabolic has been   proposed as an important mechanism for the effect of 
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alcohol on the pancreas. Alcohol is partially metabolized in the pancreas and may cause 
reduced blood flow and the generation of free oxygen radicals, which increases the risk of 
inflammation and developing acute pancreatitis[38]. Results of a systemic search reported by 
Pongprasobchai et al showed that alcohol is not the leading aetiology for acute pancreatitis and 
most of the patients had gallstone initiated disease [39]. They showed that one-fourth of the 
patients diagnosed with alcohol abuse had other causes acute pancreatitis present. Alcohol has 
been reported to induce more severe forms of acute pancreatitis and local complications, such 
as pseudocyst formation, compared with biliary acute pancreatitis [40]. Gallstones obstruct the 
pancreatic duct, thereby causing retention and stasis of pancreatic secretory fluids and the 
reflux of bile into the pancreatic duct [37, 41]. Biliary acute pancreatitis was common among 
people older than 70 years while alcoholic acute pancreatitis was high with people younger 
than 50 years [42]. In a similar study, acute pancreatitis prevalence was shown not to correlate 
with alcohol consumption, but that sex was reported as an independent risk factor. Alcohol 
remains a common cause in men but the incidence of gallstone-induced acute pancreatitis was 
similar among the men and women [43].    
 
1.1.3 Animal model of acute pancreatitis  
Several models have been used to induce acute pancreatitis in rodents and generally categorised 
as non-invasive and invasive models [44]. Non-invasive experimental models of acute 
pancreatitis are hormone-induced, alcohol-induced, immune mediated, diet-induced, and L-
arginine-induced. Invasive models used to induce acute pancreatitis are the closed duodenal 
loop model, antegrade pancreatic duct perfusion model, biliopancreatic duct perfusion model, 
combination of secretory hyperstimulation with minimal intraductal bile acid exposure model, 
vascular-induced model, ischemia/perfusion model, and the duct ligation model [44]. 
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Of the non-invasive animal models, caerulein is the most commonly used.  [45-47]. Caerulein 
is an analog of the gastrointestinal secretagogue hormone cholecystokinin (CCK) and at high 
concentrations causes the release of digestive enzymes from pancreatic acinar cells [48]. 
However, it has been shown that super stimulating concentrations of caerulein inhibits 
digestive enzyme secretion, causing premature intrapancreatic proteolytic enzyme activation, 
and induction of  acute pancreatitis [49]. In rats, caerulein causes mild oedematous acute 
pancreatitis [49], but in mice, it causes more severe, necrotizing acute pancreatitis [50]. A 
number of studies have presented several animal models of pancreatitis in different species. 
However, most studies evaluating the pathogenesis of pancreatitis use caerulein in rodents to 
induce acute pancreatitis as this induces acute pancreatitis closely resembling that in humans 
[48]. In this model the dose of caerulein and duration of caerulein injection affect the severity 
of acute pancreatitis.  
1.2 Leukocytes and inflammation  
Activation of leukocytes results in the release of pro-inflammatory mediators which are 
considered as secondary mediators and release of these mediators leads to a systemic 
inflammatory response [51]. Leukocytes play an important role in the development and 
propagation of inflammation. Neutrophils are the first line of the cellular response of the 
immune system and play a key role in the elimination of pathogens. Studies have shown that 
neutrophils contribute to the orchestration of the inflammatory response by releasing cytokines 
[52, 53]. Neutrophils also become activated by various cytokines, growth factors and bacterial 
products [54, 55].  
Monocytes and their lineage-descendant macrophages play crucial roles in tissue homeostasis 
and immunity. Monocytes are an important part of immune system playing a key role in 
inflammation, whereas tissue-resident macrophages contribute to tissue homeostasis and the 
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resolution of inflammation. In spite of the various roles of monocytes and macrophages in 
inflammation and homeostasis, they are also involved in many pathological processes [56].  
Lipopolysaccharide (LPS), or endotoxin, is an important component of the outer membrane of 
gram-negative bacteria, and is a potent activator of macrophage function leading to responses 
that can have either protective or injurious effects on the host [57]. Following activation, these 
cells secrete a large amount of nitric oxide (NO) and pro-inflammatory cytokines, such as TNF-
α, IL-1β, and  IL-6 [58]. Pro-inflammatory mediators are released by activated macrophages to 
signal the recruitment and activation of leukocytes. However, uncontrolled and excessive 
release of inflammatory mediators and the release of free radicals by leukocytes are implicated 
in pathological inflammation [59]. Therefore, understanding the signalling mechanisms that 
results in pathological inflammation is critical for the development of novel anti-inflammatory 
therapies. Furthermore, macrophages are capable of removing apoptotic cells by phagocytosis 
and secreting anti-inflammatory mediators, such as IL-10, and growth factors [58, 60]. 
Therefore, the modulation of macrophage-mediated cytotoxicity could provide a new 
therapeutic approach in various inflammatory diseases.  
 
1.2.1 Leukocytes and acute pancreatitis  
Various cells contribute to the pathogenesis of acute pancreatitis including pancreatic acinar 
cells, endothelial cells and inflammatory cells (neutrophils, lymphocytes, monocytes and 
macrophages) [61]. Neutrophil migration plays a key role in development of acute pancreatitis 
and pancreatitis-associated lung injury, which are defined as acinar cell necrosis, tissue damage 
and distal organ damage. Treatment of animals with anti-neutrophil antibody has resulted in 
partial protection of animals from acute pancreatitis [61].  
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Neutrophils are one of the main inflammatory cells involved in acute pancreatitis. An in vivo 
study of acute pancreatitis revealed that late but not early activation of trypsinogen in acinar 
cells was regulated by neutrophils in acute pancreatitis [62]. Neutrophils are stimulated by the 
pro-inflammatory cytokines such as TNF-α, IL-1β and IL-8 and migrate to remote organs, 
where they release the proteolytic enzyme elastate [63, 64]. Neutrophil elastase (NE), causes 
tissue damage by destroying elastin, collagen and fibrin which contributes to organ dysfunction 
related to acute pancreatitis [64, 65]. 
Macrophages are actively involved in acute pancreatitis and the inflammatory mediators 
released by these cells are critical in this inflammatory disorder. In the early stage of 
inflammation, macrophages exhibit a pro-inflammatory function through release of 
inflammatory cytokines and amplify the development of inflammation [66]. Macrophages have 
been shown to produce TNF-α in response to pancreatic enzymes such as trypsin, elastase, 
carboxypeptidase A and lipase released by damaged acinar cells [25, 67]. Activated 
macrophages produce more cytokines and inflammatory mediators in systemic organs and 
amplify inflammation of the pancreas [68]. During acute pancreatitis, peritoneal macrophages 
become activated and produce pro-inflammatory mediators such as TNF-α, IL-1β and IL-6 
[69]. Kupffer cells are the second family of macrophages involved in acute pancreatitis. An in 
vitro study of Kupffer cells showed that these macrophages could be activated by pancreatic 
enzymes [70, 71]. Alveolar macrophages are the third group of macrophages that contribute to 
acute pancreatitis. These cells are involved in lung damage associated with acute pancreatitis.  
 
1.3 Inflammatory mediators  
Cytokines are low molecular weight proteins produced mainly by immune cells in response to 
various stimuli. Cytokines function as signalling molecules that regulate immunity, 
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inflammation and haematopoiesis [72]. The specific names of cytokines have been reviewed 
by Zhang et al (2007) and include lymphokines (cytokines secreted by lymphocytes), 
monokines (cytokines produced by monocytes), chemokine (cytokines with chemotactic 
properties), and interleukins (cytokines produced by one leukocyte and acting on other 
leukocytes) [73].  
The number of cytokines identified so far exceeds 30, and they are pleiotropic, meaning that 
each cytokine could act on different target cells. When cytokines are produced, they have the 
ability to increase production of themselves and other cytokines. These molecules interact with 
specific receptors to initiate a response from target cells. The interaction of cytokines with 
specific cell surface receptors on target cells leads to new mRNA and protein synthesis [74]. 
Cytokines can be produced in response to pathogens and play a crucial role in innate and 
adaptive immune responses [75]. TNF-α, IL-1β, and IL-6 are three cytokines that play a crucial 
role in mounting an initial defence in response to pathogens. Excessive release of cytokines 
may result in different immune-mediated inflammatory diseases.  Consequently, cytokines and 
the control of the release of these inflammatory mediators may be potential therapeutic targets.  
 
1.3.1 TNF-α 
TNF-α is a key mediator of  the inflammatory response [76]. It is considered as one of the most 
important inflammatory mediators, and is elevated in pathological conditions such as septic 
shock [77, 78]. TNF-α and IL-1β are also central pro-inflammatory cytokines that play a key 
role in amplifying inflammation [79]. TNF-α mediates various cellular responses by binding 





IL-1β is a pro-inflammatory mediator which is produced by various cell types but derived 
predominantly from activated macrophages [82]. It plays an important role in inflammation 
and response to injury [83, 84]. Although overproduction of IL-1β is in association with the 
pathophysiological changes that occur during different disease states, such as sepsis and acute 
pancreatitis [85-87], increased levels of IL-1β do not correlate with the severity of sepsis in 
human [87].   
1.3.3 IL-6 
Like other cytokines, IL-6 is produced by most of the cells in the body but particularly 
monocytes and macrophages [88]. IL-6 is also an endogenous mediator for LPS-induced fever 
[89, 90]. A study on the central nervous system of mice revealed that IL-6 was necessary for a 
fever response to LPS treatment [91], and fever is essential for the anti-infectious response in 
mice infected with Klebsiella pneumoniae causing peritonitis [92]. 
 
1.3.4 Chemokines  
Chemokines are an important part of the host defence system against infection. Chemokines 
are members of a cytokine family with low molecular weights. There are two groups of 
chemokines: CC and CXC based on the location of cysteine. The CXC subfamily has an 
intervening amino acid between the first two cysteines. Monocyte chemoattractant protein-1 
(MCP-1) belongs to the CC chemokine family which attract monocytes to the site of 
inflammation, whereas interlukin-8 (IL-8) produced by macrophages and epithelial cells in 
human belongs to CXC chemokines  and effect neutrophils [61].   
MCP-1 regulates migration of monocytes/macrophages to the site of inflammation. It is a 
potent chemotactic factor for monocytes and macrophages. MCP-1 is produced by mesangial 
cells [93] , endothelial and smooth muscle cells [94], epithelial cells [95], and monocytes and 
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macrophages are known to be the main source of MCP-1 [96, 97]. Increased peripheral blood 
levels of MCP-1 in an animal model of sepsis [98] have been reported. MCP-1 blockade has 
been shown to be a potential intervention for the treatment of various diseases including 
rheumatoid arthritis [99], multiple sclerosis [100], atherosclerosis [101], and sepsis [102].  
Macrophage inflammatory protein 2 (MIP-2) is a murine CXC chemokine that attracts 
neutrophils, and its secretion from intestinal epithelial cells is enhanced by inflammatory 
stimuli such as IL-1β [103]. An in vivo study of the role of the epithelial cells in the mucosal 
immune system revealed that blocking MIP-2 with an anti-MIP antibody reduced neutrophil 
infiltration in intestine [104]. Macrophages [105], epithelial cells [106], endothelial cells [107], 
and neutrophils [108] have been shown to be a cellular source for MIP-2 
 
1.4 Cytokines and acute pancreatitis  
Pro-inflammatory cytokines play a key role in the pathogenesis of acute pancreatitis and its 
systemic complications. Norman et al. reported elevated levels of pro-inflammatory cytokines 
such as TNF-α, IL-1β and IL-6 in an experimental mice model of acute pancreatitis an hour 
after induction of disease [109]. They showed that there was a correlation between the levels 
of pro-inflammatory cytokines and the severity of local pancreatic destruction. Blocking IL-1β 
receptors attenuate the severity of acute pancreatitis and reduced the pancreatic damage [109].  
Several studies of acute pancreatitis in human and animal models have shown that the levels 
of inflammatory cytokines, such as IL-1β, IL-6, IL-10 and TNF-α, increase in acute pancreatitis 
and the severity of acute pancreatitis and morbidity are associated with enhanced levels of these 
cytokines [109-113]. Clinical studies have demonstrated enhanced levels of IL-6 in the 
peripheral blood of patients with acute pancreatitis. These studies revealed that raised levels of 
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IL-6 correlate with disease severity [110, 114-116]. Blocking IL-6 induced acinar cells 
apoptosis has attenuated the severity of severe acute pancreatitis in mice [117].  
IL-10 has emerged as the main anti-inflammatory cytokine that inhibits the release of pro-
inflammatory cytokines by macrophages [118, 119]. Studies using a mouse model of acute 
pancreatitis showed that IL-10 has the ability to reduce the severity of acute pancreatitis 
through the inhibition of local TNF-α production [120, 121]. Activated macrophages are known 
as principle producers of TNF-α. In experimental acute pancreatitis high levels of tissue and 
serum TNF-α levels were associated with the severity of disease and infiltration of activated 
macrophages into the pancreas [77] and blockage of TNF receptor has resulted in attenuation 
of the acute pancreatitis reduction of the inflammatory cytokines [122].  
Multiple organ failure in severe pancreatitis is mediated, at least in part, by IL-1β through the 
activation of neutrophils [123]. IL-1β levels may affect the amount of IL-6 and TNF-α 
produced in acute pancreatitis. Reduced levels of IL-6 and TNF-α were observed in an animal 
model of pancreatitis following blocking IL-1β receptor antagonist [32, 109, 123]. These 
studies support a role for inflammatory cytokines in the process of pancreatitis. Increased levels 
of TNF-α in an experimental model of acute pancreatitis was shown to regulate acinar cell 
apoptosis which may also result in the progression of acute pancreatitis [124, 125]. 
 
1.5 Chemokines and acute pancreatitis  
Chemokines are small cytokines released by different kinds of cells, directing leukocytes to the 
damaged tissues [126]. A large number of studies have shown that chemokines play a crucial 
role in the development of acute pancreatitis. Release of chemokines by acinar cells attracts 
other inflammatory cells to the pancreas and release further inflammatory mediators [3, 46, 
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127]. An in vivo study of a rat model of acute pancreatitis showed increased levels of MCP-1 
in the early stage of this disease indicating these chemokines as an important inflammatory 
mediator [127]. A study of the serum from patients with acute pancreatitis also showed elevated 
systemic levels of MCP-1. The severity of acute pancreatitis and also the development of 
multiple organ damage were found to be associated with the levels of MCP-1[128]. In a mouse 
model of acute pancreatitis, Bhatia at al. reported a crucial role for MCP-1 in acute pancreatitis 
[3]. They reported that inhibition of MCP-1 production resulted in reduced amylase, MPO 
activity and acinar cell injury and protected the mice against acute pancreatitis [3]. IL-8 is 
another important chemokine with increased levels in acute pancreatitis and its concentration 
is associated with the severity of the disease [64, 129]. This chemokine activates neutrophils 
in acute pancreatitis [64]. Increased levels of MIP-2 have been reported in a mouse model of 
acute pancreatitis, whereas blocking this chemokine with an anti-MIP-2 antibody partially 
protected mice from acute pancreatitis and associated lung injury [130]. These findings show 
that MIP-2 has an important function in acute pancreatitis. An in vivo study of acute 
inflammation in mice revealed that MIP-2 is an inducible chemokine that controls migration 
of neutrophils to the site of inflammation [131, 132]. MCP-1 has also been shown to be an 
early mediator of acute pancreatitis [3].  
 
1.6 Cell signalling pathway 
Cells receive and develop the signals that originate from their surface to respond to the changes 
in their immediate environment. Numerous intracellular signalling pathways exist which are 
involved in the transmission of the information within the cells. These signalling pathways 
consist of two main groups: The first group has signalling pathways that respond to the stimuli 
on the cell’s surface in the form of chemicals received by the receptors. These receptors use 
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transducers and amplifiers to transfer the received information from the surface of the cells to 
targets in the interior. These include mitogen-activated protein kinases (MAPKs) and nuclear 
factor κB (NF-κB). MAPKs are involved in a wide range of signalling cascades wherein 
various extracellular stimuli induce inflammation. NF-κB is one of the downstream 
components of the MAPK signalling pathway that is involved in many signalling pathways 
including proliferation, apoptosis and inflammatory responses [133]. The other group of 
signalling pathways belong to the group that are activated signals from within the cell. 
Metabolic pathways belong to this group [134]. 
 
1.6.1 NF-κB 
NF-κB is a transcriptional factor associated with gene expression early in inflammation which 
stimulates production of several cytokines such as TNF-α [135]. NF-κB activation in 
inflammation correlates with the levels of inflammatory mediators. Activation of NF-κB 
through degradation of IkB is reported in a rat model of acute pancreatitis [136]. IκB is the 
endogenous inhibitor of NF-κB and its phosphorylation leads to activation of NF-κB. 
Following activation of IκB, the released NF-κB is translocated into the nucleus to activate the 
target gene [137]. An in vivo model of acute pancreatitis demonstrated up-regulation of the 
levels of NF-κB in activated monocytes and macrophages that was associated with cytokine 
transcription and production [138].   
Increased levels of NF-κB activity has been reported in an experimental study of acute 
pancreatitis in the rat. Pancreatic tissue analysis revealed increased levels of TNF-α and NF-
κB. Administration of amobarbital, an agent that blocks NF-κB activation, resulted in reduced 
levels of TNF-α mRNA expression. These results suggested that NF-κB was a regulator of 
TNF-α production in pancreas tissue and that down-regulation of NF-κB activity stops 
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overproduction of TNF-α and ameliorates the severity of pancreatitis [139]. Elevated levels of 
TNF-α is also associated with increased activity of NF-κB in acinar cells in acute pancreatitis 
[136]. 
An experimental study of acute pancreatitis in a rat model induced by caerulein, revealed an 
important role for NF-κB in the pathogenesis of this disease. Treatment of pancreatitis 
prevented NF-κB activation in this model. Elevated expression of IL-6 was also reported in 
this model and blocking NF-κB inhibited production of this cytokine [136]. A significant 
correlation between NF-κB activation and MCP-1 production has been shown in an in vitro 
study on human mesangial cells [140] and an in vivo study of progressive proteinuric 
nephropathy and passive Heymann nephritis in rats [141]. These studies showed that NF-κB 
mediates transcription of the MCP-1 gene. Pro-inflammatory cytokines are activated through 
activation of NF-κB but these inflammatory mediators also activate NF-κB, thus amplifying 
the cytokine cascade and inflammatory response [142, 143] (Figure 1-1).   
1.6.2 MAPKs 
Phosphorylation of protein is an important mechanism for communication between external 
signals and membrane proteins that leads to the transfer of the message to the nucleus. MAPKs 
are serine/threonine protein kinases. MAPKs have the ability to transduce environmental and 
developmental signals, including growth and stress factors, into adaptive and programmed 
responses such as inflammation, apoptosis, and differentiation [144]. MAPKs are involved in 
inflammatory mediator production but these proteins are also induced by pro-inflammatory 
cytokines [145, 146]. The MAPK family consists of three subfamilies: extracellular signal-
regulated kinase (ERK); Jun N-terminal kinases (JNK); and, p38 kinase. ERK is an important 
intermediate in signal transduction pathways that are initiated by many types of cell surface 
receptors such as epidermal growth factor (EGF), reviewed by McCubrey et al [147]. 
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Activation of ERK results in phosphorylation of cytoplasmic and nuclear substrates, including 
enzymes, cytoskeleton proteins, and transcription factors [148]. 
ERK is an upstream activator of NF-κB and plays an important role in the temporal controlling 
of NF-κB transcriptional activity and expression of NF-κB-regulated genes [149, 150]. An in 
vitro study Human Embryonic Kidney 293 (HEK-293) showed that over expression of the H2S 
producing enzyme CSE, sustainably activates ERK1/2 phosphorylation [151]. In addition, 
Bhatia and co-workers showed that H2S regulates the inflammatory response in a caecal 
ligation puncture (CLP) model of sepsis through activation of the ERK pathway [152]. 
MAPKs are shown to play an important role in acute pancreatitis. Samuel et al reported that 
MAP kinases (ERK, JNK, and p38) are involved in caerulein-stimulated exocrine pancreatic 
production of cytokines. Treatment of pancreatic fragments with caerulein resulted in a 
significant increase of phospho-ERK and phospho-p38. Inhibition of ERK with PD 98059 and 
also inhibition of p38 with SB 203580 significantly reduced IL-1β and TNF-α production. The 
group used SP 600125 to inhibit JNK specifically and reported an attenuation of levels of JNK 
and IL-1β [153]. Therefore, activation of MAPKs and the production of cytokines are 
associated with inflammatory events (Figure 1-1). 
Inhibition of ERK with PD 98059, a highly specific inhibitor of ERK, in a mouse model of 
caerulein-induced acute pancreatitis resulted in attenuation of inflammation in acute 
pancreatitis [154, 155]. It was proposed that the protective effects of PD 98059 might be related 
to the inhibition of cyclooxygenase 2 (COX-2) [156]. JNK another group of MAPKs family 
has been shown to play an important role in transcription factor activation, cell proliferation, 
and apoptosis [157]. Inhibition of JNK with SP 600125 a selective and reversible inhibitor of 
JNK, resulted in amelioration of inflammation in a mice model of acute pancreatitis [158] and 





Figure 1-2. NF-κB and MAPKs pathway in the regulation of gene expression in macrophages. MAPKs will be 
phosphorylated with any stimuli and activated transcription factor NF-κB. Upon activation NF-κB will transfer to 
the nucleus and bind to DNA and up-regulate inflammatory genes. Increased inflammatory mediators also will 
activate NF-κB/MAPKs and amplify inflammation. Administration of specific inhibitors to inhibit NF-κB (Bay 
11-7082), ERK (PD 98059), JNK (SP 600125) and p38 (SB 203582) was shown to attenuate inflammation in 
different diseases. Therefore, inhibition of MAPKs family is responsible for the protection of the inflammatory 
response.  
1.7 Gaseous transmitter molecules  
Endogenously produced gases act as gasotransimitters and regulate tissue function by 
transmitting information between cells in the body [159]. Nitric oxide (NO) was the first 
gaseous transmitter shown to regulate physiology in the mammalian body [160, 161]. Further 
study of the mechanism of action and physiochemical nature of NO revealed the existence of 
other gases which are produced endogenously and also play a role in physiological functions. 
These gases are carbon monoxide (CO) and H2S [162-164]. These small signalling 
gasotransmitters (NO, CO, and H2S) have been shown to play an important role in physiology 




1.7.1 Nitric oxide  
NO is a short-lived free radical that mediates many biological functions such as host defence, 
neurotransmission, neurotoxicity, and vasodilation [166, 167]. NO is synthesized from arginine 
following activation of inducible nitric oxide synthase (iNOS) [168], and it is an important 
effector molecule involved in immune regulation and defence. Overproduction of NO leads to 
a variety of diseases, such as: atherosclerosis, malignancy, rheumatoid arthritis, tissue injury, 
and septic shock [168-170].  
Increased levels of NO are reported in activated macrophages [171, 172] and macrophage-
derived NO plays important roles in physiology, pathology, and inflammatory responses. The 
various  roles of NO including being a toxic agent against infectious organisms agents, an 
immuneregulator, and an inducer or suppressor of apoptosis have been reviewed by Coleman 
[173]. A possible interaction between H2S and NO has been reported in a study of the effect of 
NO-releasers (sodium nitroprusside) on CSE expression and H2S production in smooth muscle 
cells isolated from rats [174]. Furthermore, NO has been shown to induce an increase in 
enzymatic H2S production in vascular tissues [175]. 
 
1.7.2 Carbon monoxide  
A biological function of CO in mammalian system was proposed in 1987 when Brune and 
Ullrich (1987) reported that, like NO, CO can also activate soluble guanylate cyclase [176]. In 
addition, Verma and co-workers showed that CO like NO may contribute to biological function 
[177]. This research group also suggested that CO has a role as a neurotransmitter. The anti-
inflammatory, anti-apoptotic, and anti-proliferative properties of CO have been reviewed by 




1.7.3 Hydrogen sulfide  
There is growing evidence that H2S performs a wide range of physiological and pathological 
functions. It is now increasingly accepted that H2S is the third endogenous gaseous mediator 
alongside carbon monoxide and nitric oxide. Endogenous H2S is produced from L-cysteine 
mainly by the activity of two enzymes, CBS and CSE. In general, endogenous H2S production 
in the periphery depends on CSE [164], while CBS is primarily expressed in central nervous 
system (CNS) [179, 180]. Recent reports have shown that the production of H2S in 
macrophages depends solely on CSE and that following this production H2S acts in an 
autocrine manner [181] and signals further activation of macrophages [181-183]. This suggests 
that H2S may have an important role in signalling during inflammation. 
 
1.7.4 Interaction between CO, NO and H2S 
The interaction between CO, H2S, and NO is an interesting event that occurs in the mammalian 
body (Fig. 1). In a study on rats with hypoxia induced pulmonary hypertension by Qingyou et 
al, increased levels of plasma CO concentration and heme oxygenase 1 (HO-1) expression in 
the pulmonary artery were reported. They showed that inhibition of H2S production resulted in 
reduction of HO-1 mRNA and protein expression and as a consequence the plasma 
concentration of CO was reduced [184]. The effect of HO-1 on NO production has been 
described in a study on murine macrophages. NO derived from iNOS has been shown to induce 
HO-1 expression in LPS-stimulated macrophages [185].  
In another study, Chung and co-workers reported an interaction between CO, NO and H2S. 
They showed that H2S induced HO-1 up regulation, CO production and consequently NK-κB 
activation. In addition, iNOS expression and NO production were reduced. They also showed 
that treatment of LPS-stimulated macrophages with CO, inhibited iNOS expression and NO 
production by these cells [186]. In a similar study, the effect of CO on iNOS and NO production 
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was reported by Sawle et al. They demonstrated that CO has inhibitory effects on NO 
production and when NO concentration exceeded the homeostatic level CO acts as a feedback 
inhibitor of iNOS and consequently production of NO [185]. There is also evidence that NO 
may up-regulate CSE expression and H2S production [175, 187].   
 
Figure 1-3. Cross talk between CO, NO and H2S. Adapted from [188]. 
 
1.8 General properties of H2S 
H2S is a colourless, water-soluble gas molecule with a strong odour of rotten eggs. Its solubility 
in lipophilic solvents is almost fivefold more than in water which makes it diffusible across 
cell membranes.  H2S can be hydrolysed to hydrosulfide and sulfide ions in the following serial 
reactions:  
H2S ⇔ H+ + HS− ⇔ 2H+ + S2- 
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H2S dissociates in water or plasma into H
+ and HS- (hydrosulfide ion) with one-third remaining 
in an un-dissociated form. The latter reaction occurs only in high pH so the concentration of S-
2 is negligible in vivo [162]. 
 
1.9 Biosynthesis of H2S 
H2S is biosynthesized by the activity of several enzymes including cysteine aminotransferase, 
3 mercaptosulfurtransferase (MST), CBS and CSE. The majority of endogenously produced 
H2S is produced by the activity of two pyridoxal-5′-phosphate-dependent enzymes, CSE and 
CBS. These two enzymes facilitate production of H2S in mammalian tissues from L-cysteine 
[189-191]. Expression of both CSE and CBS enzymes is essential for the production of H2S in 
some tissues while in other tissues one enzyme activity is enough [192-196]. Therefore, 
expression of CSE and CBS is tissue specific.  
 
1.10 Physiological and pathophysiological roles of H2S 
The physiological role of H2S is now receiving increasing attention. It has been shown that 
hydrogen sulfide regulates a gradually increasing list of physiological functions. Various roles 
for H2S such as a vasodilator and blood pressure regulator [197], insulin secretion reduction 
[198], in inflammation and inflammatory diseases [1, 199, 200], an antioxidant [201, 202] and 
neuro-protection [203] have been reported recently. Disparate anti-inflammatory (‘the good’) 






Figure 1-4. Physiological/pathophysiological roles of H2S in different clinical conditions. The synthesis of H2S is 
catalysed by CSE, CBS and MST. H2S has a direct effect as a neuromodulator and anti-inflammatory activity in 
the CNS. H2S has an important role in controlling the cardiovascular system where it acts as a vasodilator. H2S 
has also been shown to have an indirect effect on oxidative stress and metabolic rate with anti-apoptotic activity.  
 
1.10.1 H2S and oxidative stress  
Oxidative stress can induce apoptosis [204]. The effect of H2S on apoptosis has been gaining 
increasing attention. It has been reported that H2S has both anti- and pro-apoptotic effects. 
Minamishima et al (2009) reported that H2S activates anti-apoptotic proteins and decreases 
apoptotic proteins [205]. Similarly, Henderson and colleagues (2009) showed that H2S 
decreased apoptosis both in vitro and in vivo [206]. Apoptosis of neurons plays an important 
role in pathogenesis of neurodegenerative diseases. It has been reported that H2S prevents 
apoptosis induced by hypoxia in cultured hippocampal neurons [207, 208].  
Antioxidant activities of H2S have been well studied. An inhibitory effect of H2S on oxidative 
stress has been shown by Yin et al [201]. Kimura and Kimura (2004) have shown that H2S 
protects neurons against oxidative stress caused by glutamate via increasing the level of 
glutathione [209]. It has also been shown that H2S has the ability to protect neuroblastoma cells 
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from oxidative stress induced by peroxynitrite and hypochlorous acid [199, 210]. The 
protective effect of H2S against oxidative stress has been shown in myocardial, liver, renal, and 
lung injury [211, 212]. On the other hand, H2S could promote ischemic damage by a direct 
degenerative effect on cerebral neurons, and inhibition of its production may represent a 
therapeutic approach to the treatment of stroke [213].  
 
1.10.2 H2S and cardiovascular system  
There is increasing attention to H2S because of its effects on the cardiovascular system. H2S 
functions as a signalling molecule in smooth muscle relaxation in the vascular system through 
activation of ATP-sensitive K+ channels [214, 215]. Therefore, H2S has the capacity to act as 
a vasodilator [174, 192, 216]. In addition, vasoconstrictive activity for H2S has been described 
[217]. H2S has been reported to act in synergy with NO to induce smooth muscle relaxation 
[192]. This was only observed with low concentrations of H2S. Biosynthesis of NO has also 
been shown to be regulated by H2S [218]. Therefore, it has been proposed that modulation of 
H2S could be used in the treatment of hypertension [219]. 
The role for H2S in regulating the circulatory system has been well studied. Zhao et al (2001) 
have shown that peripheral administration of H2S donor (sodium hydrogen sulfide (NaHs)) 
results in a short hypotensive effect. High blood pressure has been reported following inhibition 
of H2S production using CSE inhibitors [220, 221]. H2S has also been shown to have 
hypotensive and bradycardia effects through activation of ATP-sensitive potassium channel 
(KATP) channels [222]. These reports indicate a regulatory role for H2S on the activity of 
autonomic nerves and release of neuroendocrine hormone. These properties of H2S could be 




1.10.3 H2S and central nervous system 
A physiological role has been proposed for H2S in human, rat and bovine brain. This was based 
on sulfide levels measured in this tissue [224-226]. These reports initiated further study of the 
potential physiological role for H2S in the CNS. In the brain, H2S is predominately produced 
by CBS and increased levels of H2S have been reported in the hippocampus and cerebellum 
[227]. A relatively high level of H2S in the brain suggests a neuromodulator role for H2S [227]. 
An increased level of H2S has been reported following neuronal activation in the brain [228]. 
H2S has also been shown to regulate the release of corticotropin-releasing hormone from the 
hypothalamus [229]. H2S protects neurons against vascular dementia [230] and severe cerebral 
injury [202] by suppressing apoptosis. Based on these reports, a neuromodulator or transmitter 
role for H2S in the brain has been proposed [227, 228]. Therefore, H2S may function as a 
signalling molecule in neuro-modulation in the brain and H2S releasing agents could be used 
in medical applications as a neuro-protective drug. 
 
1.10.4 H2S and diabetes  
The effect of H2S on diabetes is controversial and apparently contradictory properties of H2S 
have been well documented by in vivo studies. It has been shown that the levels of H2S 
synthesised in Zuker diabetic fatty rats (a diabetic model with obesity and hyperinsulinemia) 
and streptozotocin-induced diabetic rats were higher than non-diabetic animals [231, 232]. On 
the other hand, Bocchini and colleagues (2010) showed that there is a relationship between low 
levels of H2S in the circulation and diabetes and this may cause vascular inflammation [233].  
In 2009, Wu et al reported that Zuker diabetic fatty rats showed higher expression of CSE and 
inhibition of CSE with PAG, normalized glucose levels while treating rats with amino-
oxyacetate, a CBS inhibitor, had no effect on the levels of glucose in these rats [232]. In another 
study, inhibition of CSE in streptozotocin-induced diabetic mice resulted in hyperglycaemia 
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and hypoinsulinaemia [234]. Xue and colleagues (2013) demonstrated that administration of 
NaHS, a H2S donor, to rats reduced plasma fasting glucose levels and amplified insulin 
sensitivity [235]. In contrast to this report, H2S treated rats showed decreased levels of glucose 
uptake in adipocytes [236]. These findings revealed a role for CSE-derived H2S in the 
pathogenesis of diabetes. Therefore, it is an attractive target for therapeutic manipulation of 
diabetes. However, due to the reported differences in the effect of H2S on diabetes more 
research is required to resolve this issue. 
 
1.10.5 H2S and inflammation 
Inflammation is a protective physiological reaction. Recently, H2S has been proposed as a 
novel transmitter which plays an important physiological and pathological role in mammalian 
cells and tissues. Bhatia and co-workers demonstrated that endogenous H2S is a mediator of 
inflammation. They showed that blockage of endogenous H2S generation ameliorated the 
severity of caerulein-induced acute pancreatitis and associate lung injury in an animal model 
[1]. An in vitro study on human monocytes demonstrated that elevated levels of the signalling 
molecule H2S induced cytokine secretion [237]. H2S seems to show paradoxical effects in the 
inflammatory process. It plays both pro- and anti-inflammatory roles which seem to depend on 
the experimental model and concentration of H2S used.  
 
1.10.5.1 H2S as a pro-inflammatory mediator  
A pro-inflammatory role for H2S in acute pancreatitis [200, 238], LPS-induced endotoxic shock 
[199], burn injury [239], haemorrhagic shock [240] and airway inflammation [241] has been 
described. It has been shown that tissue and serum levels of hydrogen sulfide increases in these 
diseases. Bhatia and co-workers proposed a pro-inflammatory role for H2S in a cecal ligation 
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and puncture (CLP)-induced sepsis in mice via the ERK pathway. They showed that inhibition 
of H2S production by DL-propargylglycine (PAG) reduced the phosphorylation of ERK1/2 and 
decreased degradation of IκB and activation of NF-κB [98, 152]. Another study reported by 
Collin et al. [242], proposed a key role for H2S in pathophysiology of organ damage in 
endotoxemia. They showed that inhibition of H2S production in LPS-induced endotoxamia in 
rats resulted in reduced hepatocellular, pancreatic and neuromuscular injury. Increased H2S 
synthetic activity and MPO activity in the hindpaw following induction of inflammation in rats 
by carrageenan has been reported [86]. However, these signs diminished following inhibition 
of H2S production in animals.  
A pro-inflammatory role of H2S in burn injury has been described in a mouse model [239]. 
Increased CSE expression levels and H2S production in mice were reported in burn injury. 
Inhibition of H2S production by PAG has resulted in burn-associated systemic inflammation 
evidenced by histological changes and MPO activity [239].  
 
1.10.5.2 H2S as an anti-inflammatory mediator  
H2S has also been reported to have an anti-inflammatory role in a rat model of asthma [236], 
allergic rhinitis [243], LPS-induced inflammation in cardiac myocytes [244], 
neurodegenerative diseases [245], and gastric injury [246]. Consistent with these studies, 
Sodha et al. showed that H2S protects animals from myocardial ischaemia/reperfusion injury 
and improved myocardial function [247]. An in vitro study on human neutrophils showed that 
H2S induced apoptosis of these cells and this could interfere in the inflammatory process and 
tissue damage [248]. A recent in vivo study of beta peptide-induced neuronal injury in a rat 
model revealed an anti-inflammatory role for hydrogen sulfide [249]. H2S has been shown to 
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be neuro-protective by suppressing neuro-inflammation via NF-κB pathway in amyloid β-
peptide (Aβ) induced rat model [249]. 
 
1.10.5.3 Role of H2S in acute pancreatitis  
The potential role of H2S in inflammation has attracted recent research interest. In an in vivo 
study of the role of H2S, Li et al. showed that hydrogen sulfide is a novel mediator of LPS-
induced inflammation in mice and acts as a pro-inflammatory mediator [199]. They reported 
that administration of NaHS to mice resulted in increased lung and liver MPO activity, elevated 
TNF-α levels and histological signs of lung inflammation. This potential role for H2S was 
supported by other studies showing that inhibition of H2S production by PAG exhibits anti-
inflammatory activity [1, 242, 250].  
A pro-inflammatory role of H2S in acute pancreatitis was reported by Bhatia at al. [1]. They 
showed increased CSE mRNA expression and H2S production in a mouse model of acute 
pancreatitis while inhibition of H2S production with PAG attenuated the severity of acute 
pancreatitis and associated lung injury by reducing acinar cells injury, pancreatic and lung 
MPO activity, and amylase levels [1]. Wang et al also showed that inhibition of H2S production 
with PAG protected rats against severe acute pancreatitis via induction of acinar cells apoptosis 
mediaed by a reduction of NF-κB activity [251]. These authors   showed that administration of 
NaHS (a H2S realiser) attenuated apoptosis significantly and aggravated the damage in the 
pancreas. In a similar study PAG was shown to inhibit H2S production and protect rats against 
acute pancreatitis and associated lung injury [2].   
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1.11 RNA interference 
RNA interference (RNAi) is a biological process in which RNA molecules promote post 
transcription gene silencing, typically by causing the destruction of specific mRNA molecules 
[252]. RNAi controls key biological processes such as cell growth, tissue differentiation, cell 
proliferation, and apoptosis [253]. RNAi was discovered after the detection of microRNA 
(miRNA) in the Caenorhabditis elegans genome [254]. The finding of small (∼20–30 
nucleotide [nt]) noncoding RNAs and their associated proteins that regulate the expression of 
genetic information is one of the more significant advances in genetic manipulation [255]. Lu 
et al. (2008) suggested that dysfunction of miRNA is linked to cardiovascular disease, 
neurological disorders, and many types of cancers in human [256]. Small interfering RNA 
(siRNA) is another type of RNAi. It is produced endogenously but it is possible to produce this 
exogenously and transfer into a cell using a vector.  Synthetic siRNA is used to selectively 
silence the expression of a gene of interest.  
 
1.11.1 Bio generation and action of siRNA 
SiRNA is a potent technique to knockdown gene expression post-transcriptionally. Interest has 
been directed toward RNAi when it was shown that double stranded RNA has the ability to 
silence gene expression in the nematode worm Caenorhabditis elegans [254]. Following this 
finding, Elbashir et al. demonstrated that synthetic siRNA was capable of sequence-specific 
gene knockdown in a mammalian cell line [257]. In 2002, siRNA was used successfully for 
gene silencing in a mouse model of hepatitis C [258]. In another study, siRNA was used to 
silence CD14 in macrophages and this treatment inhibited secretion of IL-6, TNF-α, MIP-2, 
and NO production in LPS treated RAW 264.7 cells [259]. It has also been shown that siRNA 
has the ability to silence targeted genes in a variety of diseases including liver cirrhosis [260, 
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261], ovarian cancer [262, 263], bone cancer [264], human papilloma virus [265], 
erythropoietin deficiency [266], hepatitis B virus [267, 268], and colon cancer [269].   
Sequence-specific siRNA mediates the cleavage of the targeted mRNA and attenuates the 
production of specific target proteins [257]. It has been documented that synthetic siRNA 
sequences have proven to be a valuable way of reducing gene expression both in vitro and in 
vivo [254, 257, 270, 271]. Therefore, siRNA has promise as a novel therapeutic strategy and 
may be used as a tool for functional genomics to elucidate genes controlling disease pathways 
[272, 273].  
Following transfection into the cytoplasm of cells, siRNA will be incorporated into a protein 
complex called the RNA-induced silencing complex (RISC) [274]. Argonaut 2, a catalytic 
component of RISC, cleaves the siRNA sense strand [275]. Following the splitting of siRNA, 
the activated RISC will move with the attached antisense strand of siRNA and selectively 
degrade the mRNA that corresponds to this antisense strand [276]. As more mRNA target is 
destroyed by the activated RISC complex this results in gene silencing [277]. SiRNA ensures 
a therapeutic effect for 3-7days in cells which are dividing rapidly and several weeks in non-
dividing cells [278]. In order to have a persistent effect, it is important to have repeated 
administration of siRNA because it could drop below the therapeutic threshold or be degraded 
inside the cell.  
 
1.11.2 Small regulatory RNAs in cellular function 
An overview of the RNAi pathway in the cells is given in figure 1.5. When administrated 
siRNA has entered into a cell, it will be trimmed down to an appropriate size by an enzyme 
called Dicer [279]. The trimmed double stranded (dsRNA) siRNA will be loaded on to 
Argonaute protein by Dicer and dsRNA-binding protein (dsRBP). These three proteins exist in 
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the cytoplasm and constitute a complex called RNA-induced silencing complex (RISC) which 
is responsible in trimming siRNA to proper size and loading it on to the Argonaute protein 
[280]. The RISC directs gene silencing of both miRNA and siRNA pathways in plants and 
animals. The antisense strand (the guide) will bind to Argonaute and the sense strand (the 
passenger) will be removed from the complex [281]. The antisense strand of siRNA will sit 
specifically on the mRNA to cut or inhibit translation.    
 
 
Figure 1-5. The RNAi Pathway in the cell. Reproduced from [255].   
 
1.11.3 Modes of siRNA administration  
SiRNA can be delivered locally or systemically. Availability of siRNA in the target organ or 
tissue is the main challenge for in vivo delivery of siRNA. The advantages of local delivery of 
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siRNA are higher bioavailability and reduced adverse effects. In systemic delivery of siRNA 
it is injected intravenously. The possibility of being detected and cleared by cells of the immune 
system could be an issue for the particle travelling toward the target organ. SiRNA has also 
been applied topically for local treatment of skin and tumors [282, 283].   
 
1.11.4 SiRNA in research and clinical trials  
Lipid nanoparticles (LNP) are highly capable of delivering siRNA to the liver and silence a 
number of different hepatocyte gene targets in animals [284-286]. In a recent study, 
administration of LNP-formulated siRNA targeting CCR2 mRNA in mice resulted in the 
reduction of monocyte migration to the site of inflammation [101]. They showed reduced 
inflammatory atherosclerosis, tumour size, tumour associated macrophages and myocardial 
infarct size following silencing of CCR2 with siRNA [101]. 
The first clinical trial of LNP-formulated siRNA in humans was initiated by Tabernero et al. 
in cancer patients with liver involvement [287]. They applied siRNA to target the genes 
encoding two key proteins in the growth of the cancer cells, vascular endothelial growth factor 
(VEGF), and kinesin spindle protein (KSP). Analysis of sample biopsies from patients revealed 
the presence of siRNA in the tumour samples. Down-regulation of targeted genes, antitumor 
activity and regression of liver metastases in endometrial cancer were reported in this study. 
They also showed that bi-weekly intravenous injection of LNP-formulated siRNA was safe 





1.12 Research hypothesis  
It is hypothesised that the CSE enzyme activity affects the inflammatory response to LPS-
treated murine macrophages. Because CSE enzyme plays a role in acute pancreatitis it is 

















1.13 Objectives  
 To determine CSE expression by murine and human macrophages (Chapter 3 and 6). 
 To assess if the levels of pro-inflammatory cytokines produced by RAW 264.7 cells 
depend on the concentration and treatment time of LPS (Chapter 3).   
 To determine the role of CSE in activated murine macrophages by silencing CSE gene 
expression using siRNA (Chapter 4). 
 To determine the effect of silencing CSE gene expression in murine macrophages on 
NF-κB and MAPKs (Chapter 4). 
 To examine the effect of CSE gene silencing using siRNA on a mouse model of acute 
pancreatitis (Chapter 5). 
 To determine the effect of inhibition of NF-κB and MAPKs on CSE gene expression in 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Cell lines  
The murine macrophage cell line RAW 264.7 cells was grown in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 μg/ml 
streptomycin. RAW 264.7 cells were maintained via weekly passage and utilized for 
experiments at 70-80% confluency.  
2.1.2 Human primary macrophages 
Human primary macrophages were prepared in Associate Professor Steven Gieseg’s laboratory 
the University of Canterbury, Christchurch, New Zealand.  
 
2.1.3 Culture media 
Dullbecco’s modified Eagle’s medium (DMEM; Gibo BRL, USA) containing 10% heat 
inactivated fetal bovine serum (FBS; Gibo BRL, USA) supplemented with penicillin (100U/ml; 
Gibco BRL, USA) and streptomycin (100 µg/ml; Gibco BRL, USA) was used for RAW 264.7 
cell culture. Roswell Park Memorial Institute medium (RPMI; Gibco BRL, USA) containing 
10% heat inactivated human serum supplemented with penicillin (100U/ml; Gibco BRL, USA) 
and streptomycin (100 µg/ml; Gibco BRL, USA) was used for human primary macrophage 




Lipopolysaccharide was purchased from Sigma (Cat. No. L-2630) and dissolved in sterile PBS 
to reach the final growth media concentration of 100ng/ml.  
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2.1.5 Kits 
The DuoSet ® ELISA Development System for mice was purchased from R&D Systems 
(Minneapolis, MN, USA) to measure cytokines and chemokines. The M-MLV first strand kit 
(Invitrogen) was used for cDNA synthesis. The PCR kit was purchased from Bio line to 
perform PCR and quantitative PCR. Invivofectamin (a reagent for in vivo delivery of siRNA, 
Cat. No. 1377505) and RNAiMAX (a reagent for in vitro delivery of siRNA, Cat. No. 
13778100) were purchased from Invitrogen to deliver the siRNA in both in vitro and in vivo 
experiments. These lipid based nanoparticles are optimised for in vitro and in vivo siRNA 
transfection delivery. Float-A-Lyzer is a dialysis device which was purchased from Spectrum 
(Cat. No. SPECG235031). Ethylidene-pNP-glucose-7 (EPS) and α-glucosidase (Thermo 
Fisher Scientific, Middletown, VA) to measure amylase. TransAmTM NF-κB p65 




Primers were designed using primer 3. The following parameters were considered in designing 
primers: Melting temperature between 57°C -65°C, length between 100-300bp and the primer 
sequence between 17bp and 25bp (less than 17bp non specificity and more than 25bp high 
annealing temp). The accession numbers of CSE (NM_145953) and CBS (NM_001271353) 
provided in NCBI were used in designing the primers. Primers for 18S was based on previous 
publication [288]. The sense and antisense primer used for mouse and human CSE, mouse 
CBS, iNOS, 18S and beta actin are shown in Table 2-1.    
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Table 2-1. PCR primer sequences, optimal amplification cycles, optimal annealing temperature 
and product size. 
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2.1.7 Small interference RNA 
Lipid-based nanoparticle encapsulated siRNA (accession number NM-145953) against the 
CSE gene was purchased from ambion (Invitrogen) for in vitro and in vivo experiments in this 
study. Negative siRNA (scrambled siRNA) that has the same nucleotide composition but with 
a different sequence was used as a negative control (Invitrogen). 
 
2.1.8 Antibodies 
The following primary antibodies were used in this study. Mouse monoclonal antibody (M01), 
clone 4E1-1B7 (1:1000) (Cat. No. H00001491-M01) (Abnova) against CSE, Rabbit 
monoclonal antibody against CD11b (1:250) (Cat. No. 133357) (Abcam), Rabbit monoclonal 
antibody against phospho-p44/42 MAPK (Erk1/2) (1:5000) (Cat. No. 9101) (Cell Signalling), 
rabbit monoclonal anti-p44/42 MAPK antibody (1:5000) (Cat. No. 9102) (Cell Signalling), 
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rabbit polyclonal antibody against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Cat. 
No. 25778) (Santa Cruz) (1:1000), and rabbit polyclonal IgG antibody against hypoxanthine 
phosphoribosyl transferase 1 (HPRT) (1:5000) (Cat. No. 20975) (Santa Cruz). The secondary 
antibodies were goat anti-mouse IgG-HRP conjugated secondary antibody (1:10000) (Cat. No. 
2005) (Santa Cruz) goat anti-rabbit IgG H&L (Alexa Fluor 488) (1:500) (Cat. No. 150057) 
(Abcam), and goat anti-mouse IgG-HRP conjugated (1:5000) (Cat. No. 31460) (Thermo 
Scientific).  
 
2.1.9 SDS-PAGE and western blotting 
Prestained recombinant protein (Cat. No. 161-0374) molecular weight markers and 30% 
Acrylamide/Bis solution (Cat. No. 1610157) were obtained from Bio-Rad. Ammonium 
persulphate (APS), NNN’N’-tetramethylethylenediamine (TEMED), glycine were purchased 
from Sigma. Nitrocellulose blotting membrane (Cat. No. 10401196) and filter paper 
(Whatman™ 3030-861) were obtained from GE Healthcare (Little Chalfont, UK). Glycerol 
was purchased from Thermo Fisher Scientific. The chemiluminescence detection kit was 
purchased from Perkin Elmer.  
2.1.10 Caerulein 
Caerulein was purchased from Bachem California (Torrance, CA). 
 
2.1.11 Drugs 
Pentabarbitone sodium (provet) was prepared by the Christchurch Animal Research Area 
(CARA) to euthanize the animals. Temgesic (0.2mg/kg) was used to control the pain in mice 
before administration of caerulein.  Temgesic (provet) was provided by CARA. 
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2.1.12 Dyes 
Trypan blue and bromophenol blue and were purchased from Sigma.  
 
2.1.13 Signalling pathway inhibitors 
Bay 11-7082 (NF-κB inhibitor), PD 98059 (ERK inhibitor), SB 203580 (p38 inhibitor) and SP 
600125 (JNK inhibitor) were purchased from Sigma Aldrich and diluted in sterile filtered 
dimethyl sulfoxide (DMSO) (Sigma).  
 
2.2 Methods 
2.2.1 Cell culture and treatment 
2.2.1.1 Cell counting 
 
Cells were counted using a haemocytometer. For this, 20µl of trypsinized cells were added to 
20µl 0.4% trypan blue solution. This mixture was placed into a haemocytometer chamber and 
viewed under light microscope. Cell count was determined by multiplying the number of cells 
calculated in 16 small squares (corners of the haemocytometer) with the dilution factor and 104 
to give number of cells per ml. Dead cells stained blue. Viability was determined as the 
percentage of live cells (unstained cells) over the total cell number.  
 
2.2.1.2 Treatment of RAW 264.7 cells 
Lipopolysaccharide (LPS) is an effective immunologic treating agent which is widely used for 
the activation of macrophages. In this study we assessed the response of RAW 264.7 cells to 
treatment with lipopolysaccharide (LPS) (1μg/ml, Sigma, Cat. No. L-4391). Two hundred 
thousand cells were seeded in each of 6 well plates and incubated with different concentrations 
of LPS at 6 hour and 24 hour time points. Morphological changes of cells were evaluated and 
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the images were captured using an Olympus CK2 microscope (Olympus, Shinjuku, Tokyo, 
Japan) equipped with an Olympus DP-21 digital camera (Olympus, Shinjuku, Tokyo, Japan). 
 
2.2.1.3 Human primary macrophage preparation 
Human monocyte derived macrophages were prepared using unlinked blood (without access 
to the details of individuals) donated by hemochromatosis patients at the NZ Blood Bank 
(Riccarton Road, Christchurch) under ethics approval CTY/98/07/069 from the New Zealand 
Upper South B Ethics Committee as described previously [289]. Briefly, monocytes were 
isolated from human blood by density gradient centrifuging in the presence of Lymphoprem 
TM (Axis-Shield PoC AS (Oslo, Norway)) as per the manufacturer’s instruction. Cells were 
washed in sterile phosphate buffered saline (PBS) containing 150 mM sodium chloride and 10 
mM sodium dihydrogen orthophosphate for four times. Following a 40 hour incubation period 
in serum free RPMI-1640 in non- adherent plates at 37 °C, 5% CO2, cells were plated into 12-
well adherent plates at a cell density of 5 × 106 cells/well in RPMI 1640 media supplemented 
with 10% heat-inactivated human serum, 100 U/ml penicillin and 100 μg/ml streptomycin. 
Media was changed every three days and only in the first day, Granulocyte-macrophage 
colony-stimulating factor (GM-CSF) at 3 μg/ml was added to the media after seeding of the 
cells. The monocytes were incubated at 37 °C, 5% CO2 and differentiated into adherent 
macrophages over 7 to 14 days. The cells differentiate into macrophages mainly based on them 
forming the poach edge shape of macrophages. Macrophages were tested for esterase activity 
and CD markers. Sometimes, they do not change to flattened large macrophages and stay like 
monocytes, or they change in myocyte shaped cells. 
 
2.2.1.4 Treatment of human primary macrophages 
Cells were treated with Bay 11-7082 (10-30µM), PD 98059 (10, 20, 30, 50µM), SB 203580 
(10-50µM) and SP 600125 (20-30µM) for 50 minutes to inhibit NF-κB, ERK, p38 and JNK 
pathways respectively. Control cells were treated with DMSO.  Fifty minutes after treatment 
with inhibitors, the media was changed with fresh RPMI and the cells were treated with LPS 
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(1µg/ml). CSE protein expression with human primary macrophages was not detected after 
treatment of these cells with LPS for 24h, therefore, these cells were treated with LPS for 48h.  
 
2.2.1.5 SiRNA transfection (In vitro) 
SiRNA transfection was performed with different siRNA concentrations and incubation times 
to determine the efficient dose of siRNA by which to silence the CSE gene. Reverse 
transfection was performed with lipofectamin RNAiMAX (Invitrogen) with a 24 hour 
incubation in a serum free medium (Opti-MEM, Invitrogen) in accordance with the 
manufacturer’s instruction. SiRNA was mixed with transferring buffer and was placed in 6 
wells plate prior to seeding RAW 264.7 cells (7× 105/well). At 24 hours post transfection the 
media were changed with normal medium containing serum and antibiotic.  
 
2.2.2 Molecular methods 
2.2.2.1 RNA extraction 
Total RNA was extracted from RAW 264.7 cells using TRIzol (Invitrogen) following the 
manufacturer’s instruction. Briefly, cells were harvested using trypsin and homogenized in 
TRIzol reagent (1ml per 5-10 × 106). Chloroform (100 µl) was added to the homogenate, and 
samples were shaken, and incubated for 10 minutes at RT and then centrifuged for 15 minutes 
at 12000 g at 4°C. The aqueous phase was transferred to a fresh tube and RNA was precipitated 
by isopropyl alcohol (250 µl) and centrifuged for 10 minutes at 12000 g at 4°C. The pellet of 
RNA was washed with 75% ethanol and centrifuged for 5 minutes at 12000 g at 4°C. The 
spectrophotometer (Thermo Fisher) was used to quantify the RNA by measuring the 
absorbance at 260 nm (A260). The purity of RNA was determined by an A260/A280 ratio of 
between 1.6 and 2.0.  
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2.2.2.2 cDNA synthesizing (RT-PCR) 
Five micrograms of RNA were reverse transcribed using a M-MLV first strand kit (Invitrogen) 
and stored at -20°C.  
 
2.2.2.3 Conventional PCR 
One microliter of cDNA was used as a template for PCR amplification by using BIOTAQ PCR 
kit (Bio Line). No template control was performed to ensure that no PCR reagent contamination 
is present. A PCR reaction mix was prepared. The PCR reaction mix (Table 2-2) was first 
denatured at 95°C for 2 minutes, followed by an optimal cycle number which is in the linear 
range of amplification. Each cycle consisted of 95°C for 15 seconds, annealing step (60°C) for 
15 seconds (Table 2.1), and a 72°C elongation step for 15 seconds. The final extension was at 
72°C for 10 minutes. The PCR products were analysed on 1% w/v agarose gels containing 
0.1% syber safe (Thermo Fisher) (See section 2.2.26). β-actin and r18S were used as 
housekeeping genes to normalize the CSE mRNA expression in RAW 264.7 cells and human 
primary macrophages, respectively. The sequences for primers are provided in table 2-1.  
 
Table 2-2.  Master mix reaction for PCR 
 
Stock  Final Volume for 1× reaction  
Buffer 10× 1× 2µl 
MgCL2  50mM 2.5 1µl 
dNTP 5mM 0.2mM 0.8µl 
DNA Taq polimares 5U/µl 0.5U 0.1µl 
Primer 1 (Forward) 5mM 5µM 0.8µl 
Primer 2 (Revers) 5mM 5µM 0.8µl 
H2O  13.5µl 
cDNA 15µl 1µl 
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2.2.2.4 Quantitative PCR 
Real-time quantitative PCR was performed using the Eco Real Time PCR system (Illumine). 
One microliter of cDNA was used as a template for PCR amplification. No template controls was 
used. All reactions were done in triplicates. The PCR reaction mix (Table 3) was first subjected to 
95°C for 2 minutes, followed by a 40 cycles of amplification. Each cycle consisted of 95°C for 15 
seconds, annealing temperature of 55°C for 15 seconds, and an elongation temperature of 72°C for 
15 seconds. To have reliable and accurate interpretation of qPCR data it is necessary to 
normalise to the reference gene as an internal control. Beta actin and r18s are commonly used 
as reference genes for normalisation in qPCR [290, 291]. Beta actin was used as a housekeeping 
gene to normalise the mRNA expression for real-time PCR experiments in RAW 264.7 cells. For 
human primary macrophages r18S was used as a housekeeping gene to normalise the mRNA 
expression for real-time PCR experiments. Assays were performed in triplicate and the results 
are shown as mean ± standard deviation.  The sense and antisense primers were used for CSE, 
CBS, iNOS, 18S and Beta Actin (Table 2-1). 
In qPCR a positive reaction is detected by accumulation of a fluorescent signal. Evagreen 
fluorescent dye (Bioscience) is a DNA-binding dye with features ideal for use in quantitative 
real-time PCR. The Ct (cycle threshold) is defined as the number of cycles required for the 
fluorescent signal to cross the threshold. A comparative CT method was used to compare the 
CSE mRNA levels of untreated and treated cells. In the comparative method of qPCR data 
analysis, the Ct values obtained from two different experimental RNA samples are normalized 




  Chapter 2 
Table 2-3. Master mix reaction for qPCR. 
Stock  Final Volume for 1× reaction  
Buffer 10× 1× 2µl 
MgCL2 25mM 3.2 1µl 
dNTP 25mM 0.2mM 0.8µl 
DNA Taq polimares 5Uµl 0.5U 0.1µl 
Primer 1 (Forward) 5mM 5µM 0.8µl 
Primer 2 (Revers) 5mM 5µM 0.8µl 
H2O  12.5µl 
Evagreen  1µl 
cDNA 1µl 1µl 
 
2.2.3 Protein assays 
2.2.3.1 Protein extraction 
Cells were harvested and lysed in a lysis buffer consisting of 50nM Tris/HCl pH: 8 (1M), 
150mM NaCl (5M), 10% Glycerol, 1% Igepal and 1% protease inhibitor (Thermo Scientific). 
The cell lysates were vortexed vigorously for 15 seconds and were kept at 4°C. The process 
was repeated three times every 15 minutes. 
 
2.2.3.2 Nuclear Protein extraction 
Nuclear protein was extracted according to the protocol from Sigma, with minor modifications. 
The following buffers were prepared to extract the nuclear protein. Hypotonic lysis buffer: 10 
mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.1DTT and protease inhibitor cocktail. 
Extraction buffer: 20 mM HEPES (pH 7.9), 1.5 mM MgCl2, 0.42 mM NaCl, 0.2 mM EDTA, 
25% Glycerol, 0.1 DTT and protease inhibitor cocktail. Briefly, cells were washed twice with 
PBS and scraped using fresh PBS then centrifuged for 5 minutes at 450g. The pellets were 
resuspended using 400µl of lysis buffer, incubated for 15 minutes at 4°C and centrifuged for 
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5min at 420g. The pellets were resuspended in 250µl lysis buffer and passed through a No.20 
gauge needle using a single rapid stroke. Cells were then centrifuged for 20min at 5000g. The 
pellets were resuspended with 60µl of extraction buffer, shaken for 30min at 600g at RT and 
centrifuged for 5min at 11000g. The supernatants were transferred into fresh tubes and stored 
at -70°C.  
 
2.2.3.3 DC Protein assay 
The protein concentration was determined using the DC protein assay (Bio-Rad) in accordance 
with manufacturer’s instruction. Briefly, 20µl of reagent C was added to 1ml of the reagent A 
and vortexed. Twenty five microliters of this solution was added to each well of 96 well plate 
followed by adding 1µl of the sample and 200µl of reagent B. The plate was incubated 10-
15min in room temperature to develop blue colour. The absorbance in 570 nm wavelength was 
performed using a microtiter plate reader (Thermo Scientific). Standard curve was constructed 
using BSA (Gibco, Life technologies) (stock solution 1mg/ml) as standard sample in a range 
between 1-100µ/ml. In order to obtain concentrations of the buffer compounds compatible with 
the assay and the one of the sample inside the range of the curve constructed the samples were 
diluted 10× in PBS.   
 
2.2.3.4 Western blot 
Cells were harvested and lysed in lysis buffer consisting of 50nM Tris/HCl pH: 8 (1M), 150mM 
NaCl (5M), 10% Glycerol, 1% Igapal and 1% protease inhibitor (Thermo Scientific).  The cell 
lysates were vortexed vigorously for 15 seconds and were kept at 4°C. The process was 
repeated three times every 15 minutes. The samples were centrifuged at 20,000g, 20min at 4°C 
and the supernatant was stored in -80°C. Sodium dodecyl sulfate polyacrylamide gel 
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electrophoresis (SDS-PAGE) was performed using the MiniProtean® chamber system (Bio-
Rad, Hercules, CA, USA) with running buffer (see section 2.2.26). Aliquots of protein (20µg) 
were mixed 1:3 with 3× sample loading buffer (see section 2.2.26) and 1:3 H2O and denatured 
at 95°C for 5min. Samples were loaded and electrophoresed for 50-60min at 200V.  
Proteins separated by SDS-PAGE were transferred from gels to nitrocellulose membrane, using 
the Mini Trans-blot® electrophoretic transfer cell (Bio-Rad, Hercules, CA, USA) with ice-cold 
transfer buffer (see section 2.2.26) for 1h at 100V. The membranes were blocked in 5% (w/v) 
non-fat milk in Tris-buffered saline (TBS) (see section 2.2.26) with 0.05% (v/v) Tween 20 
(TBST) for 1 hour at room temperature and were incubated with the primary antibody (see 
section 2.1.8) overnight at 4°C with gentle agitation. The following day the membranes were 
washed for 5min with TBST three times, and were incubated with a secondary horseradish 
peroxidase-conjugated antibody (see section 2.1.8) for 1 hour at room temperature. The 
membranes then were washed for 15 mins with TBST for three times. An enhanced 
chemiluminescence detection kit (PerkinElmer, USA) was used to visualize immunoreactive 
proteins. Hypoxanthine guanine phosphoribosyltransferase (HPRT) or glyceraldehyde 3-
phosphate dehydrogenase) (GAPDH) was used as the housekeeping protein to normalise 
protein loading. All of the antibody dilution was performed in blocking solution (5% non-fat 
milk in 0.05% Tween in TBS). A chemi-doc system was used for detection and quantification 
(Uvitec, Cambridge, UK). The intensity of bands was quantified using UVband image analysis 
software. The data were normalised with housekeeping genes and expressed as fold increase 
over control.    
 
2.2.3.5 Homogenisation of tissues 
Pancreas and lung samples were homogenised as reported previously [45]. Briefly, 50 mg of 
tissue was weighted and placed in precooled tubs in ice and add 1ml of chilled sodium 
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phosphate buffer (PH 7.4) (see section 2.2.26) with protease inhibitor (1:100). Tissues were 
snipped with scissors and then homogenised with a blender/homogeniser until the maximum 
level of homogenisation is reached. Samples were centrifuged at 10,000g for 10min and the 
supernatant was transferred in a pre-cooled tube and stored in -80°C.  
 
2.2.3.6 Enzyme-linked immunosorbent assay 
A 96-well high-binding flat-bottom microplate (Corning) was coated with 100μL per well of 
capture antibody, diluted to 0.8 μg/mL in PBS and incubated overnight at room temperature. 
The plate was washed three times with wash buffer (0.05% Tween 20 in PBS), blocked with 
300μL of reagent diluent (1% bovine serum albumin in PBS, 0.2 μm-filtered) for 1 hour at 
room temperature and then washed three times with wash buffer. Cell supernatant samples 
were diluted in reagent diluent and 100 μL of the sample was added to each well and incubated 
for 2 hours at room temperature. The plate was washed three times with wash buffer and 
incubated with 100 μL of detection antibody, diluted to 200 ng/mL in reagent diluent, per well 
for two hours at room temperature. The plate was washed three times with wash buffer and 
incubated with 100 μL of streptavidin-HRP, diluted 1:200 in reagent diluent, for 20 minutes at 
room temperature in the dark. The plate was washed three times with wash buffer and incubated 
with 100 μL of substrate solution per well for 10 minutes at room temperature in the dark. 50 
μL of 2N H2SO4 was added to each well to stop the reaction. The absorbance was determined 
at 450 nm and corrected with absorbance at 540 nm for optical imperfections in the plates using 
microtiter plate reader (Thermo Scientific). The results were corrected to protein concentration.  
 
2.2.3.7 NF-κB activity assay 
The binding of NF-κB to DNA was measured in nuclear extract using an ELISA based 
TransAmTM NF-κB p65 transcription factor assay kit (Active Motif) as per the manufacturer’s 
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instruction. Briefly, nuclear extracts (20µg) were incubated in a 96-well plate with complete 
lysis buffer for 1h followed by incubation with a specific primary antibody against NF-κB p65 
for 1h. Subsequently, a horse radish peroxidase (HRP)-conjugated secondary antibody was 
used for detection. The enzymatic product was quantified at 450 nm using a microtiter plate 
reader (Thermo Scientific). The specificity of the assay was determined by wild-type or 
mutated comparative control wells. Results were expressed as fold increase over control 
groups. 
 
2.2.3.8 Griess assay 
The Griess assay was used to measure the total nitrite and nitrate content (nitric oxide 
metabolism) to determine NOx levels [272]. Briefly, the samples were incubated with 10 U/ml 
nitrate reductase (β-NADPH; Sigma), supplemented with 60 mM NADPH (Sigma) and 1 
mMFAD (Sigma) for 30 minutes at 37 °C in the dark to convert nitrate to nitrite. The Griess 
reagent (1 % sulfanilamide, 0.1 % N-NED, 2.5 % H3PO4; Sigma) was added in equal volumes 
and incubated for 15 minutes in the dark. The absorbance was then measured at 540 nm using 
a microtiter plate reader (Thermo Scientific), and the concentration was calculated using 
sodium nitrate standards. 
 
2.2.3.9 MTT assay 
The 3-(4, 5-dimethylthiazole-2-yl)-2, 5-biphenyl tetrazolium bromide (MTT) test was 
performed to assess the cell viability. Briefly, cells (2 × 104) were seeded in a 96 well plate. At 
24 hours post siRNA transfection, cells were treated with LPS for 24 hours. The following day 
the MTT solution (20µl per 100µl medium) was added to the wells and incubated at 37°C for 
4 hours. Acid-isopropanol (100µl of 0.04 N HCl in isopropanol) was added to wells, mixed 
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thoroughly and incubated for 8 hours. The absorbance in 570 nm wavelength was performed 
using a microtiter plate reader (Thermo Scientific). 
 
2.2.3.10 Amylase activity measurement  
A standard kinetic spectrophotometric assay was used to measure amylase activity. Briefly, 
plasma samples were incubated with the ready-to-use assay mixture containing ethylidene-
pNP-glucose-7 (EPS) and α-glucosidase (Thermo Fisher Scientific, Middletown, VA). EPS is 
a substrate for α-amylase; upon cleavage the resulting smaller fragments are acted upon by the 
α-glucosidase to yield the final chromophore measured at 405 nm. Measurements were taken 
at 60 seconds intervals for a total of 6 minutes. The resulting change in absorbance was used 
to calculate amylase activity in accordance with the manufacturer's instruction. 
 
2.2.3.11 Myeloperoxidase (MPO) 
Neutrophil sequestration in the pancreas and lung was quantified by measuring tissue MPO 
activity. Tissue samples were thawed, homogenized in 20 mM phosphate buffer (pH 7.4), 
centrifuged (13,000 × g, 10 min, 4°C) and the resulting pellet was resuspended in 50 mM 
phosphate buffer (pH 6.0) containing 0.5% w/v hexadecyltrimethylammonium bromide 
(Sigma-Aldrich). Four cycles of freezing and thawing of the suspension was undertaken 
followed by sonication for 40 seconds. The samples were then centrifuged (10,000 × g, 5 
minutes, 4°C) and the supernatants were used for the MPO assay. The reaction mixture which 
consisted of the supernatant (50 μl), 1.6 mM tetramethylbenzidine, 80 mM sodium phosphate 
buffer (pH 5.4) and 0.3 mM hydrogen peroxide (reagent volume: 50 μl). This mixture was 
incubated at 37°C for 110 seconds. The reaction was terminated with 50μl of 0.18 M H2SO4. 
The absorbance measured at 450 nm using microtiter plate reader (Thermos scientific). This 
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absorbance was then corrected for the protein content of the tissue sample. The results were 
expressed as fold increase over control. 
 
2.2.4 Animal model  
2.2.4.1 Acute pancreatitis induction  
All experimental procedures were approved by the animal ethics committee of the University 
of Otago, Christchurch, New Zealand. The severity of the acute pancreatitis induced by 
caerulein was reported to the animal welfare office. Twenty four healthy male BALB/C mice 
(8-9 weeks old) were divided into three experimental groups: the acute pancreatitis group 
(received caerulein), control mice (received saline), and the siRNA group (treated with siRNA 
24h before induction acute pancreatitis). The experiments were performed in different days to 
compare the effect of caerulein and siRNA treatment on control mice using different groups of 
animals. This was necessary to score the severity of acute pancreatitis induction in mice 
compared with control group and also to avoid possible variation in this set of the experiments. 
Based on the availability of the number of animals 1-2 mice were used for each group during 
few months (Table 2-4). Based on the availability of the samples an ELISA was run for 6-8 
mice, but the number of animals used for amylase and MPO was kept 8 for each group. 
Table 2-4. Number of the mice used for induction of acute pancreatitis and siRNA treatment. 
Time Saline Caerulein siRNA + Caerulein 
First experiment 2 2 2 
Second experiment 1 1 2 
Third experiment 2 1 2 
Fourth experiment 1 2 1 
Fifth experiment 2 2 1 
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Mice were given hourly intraperitoneal (IP) injection of saline or saline containing caerulein 
(50 µg/kg) for 10 hours as described previously [45, 292]. To control the pain, mice received 
caerulein treated with Temgesic (0.2mg/kg) 1h before starting the experiment and repeated 
every 4 hours. One hour after the last caerulein injection, mice were euthanized with a lethal 
(I.P) dose of pentabarbitone sodium (150 mg/kg). Tissue samples from the pancreas, lung and 
spleen were harvested and frozen immediately in liquid nitrogen and were stored in -80°C. 
Heparinised syringes were used to collect blood samples from right heart ventricle. Blood 
samples were centrifuged (1000g for 10 min, 4°C) and plasma was stored at -80°C for amylase 
measurement.  
 
2.2.4.2 Blok-it Alexa Flour 
Lipid based nanoparticles are non-toxic reagents that are commonly used for siRNA delivery. 
The BLOCK-iT™ Alexa Fluor® Red Fluorescent (Invitrogen) is a perfect indicator of lipid-
mediated transfection efficiency for RNAi experiments. Transfection efficiency was confirmed 
using Block-iT Alexa Fluor Red Fluorescent oligo (Invitrogen) in accordance with the 
manufacturer’s instruction. Block-iT Alexa Fluor Red Fluorescent was used to track in vitro 
and in vivo transferring of nanoparticles into the RAW 264.7 cells and blood monocytes in 
mice, respectively. Intravenous (IV) injection was performed to transfer fluorescent labelled 
siRNA into the blood monocytes of mice.  
 
2.2.4.3 Immunohistochemistry 
Immunohistochemistry was performed to examine the protein expression levels of CD11b and 
CSE enzyme and also to localize their expression in the tissues. Briefly, pancreas and spleen 
samples were isolated and immediately fixed in 10% pH-neutral phosphate-buffered formalin 
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solution. The fixed tissues were then embedded in paraffin. 5 μm of paraffin sections were 
deparaffinised and hydrated. Antigen retrieval was performed in a 10 mM sodium citrate buffer 
(pH 6.0) preheated to 95°C for 30 minutes. Immunohistochemical staining was performed on 
tissue sections using the mouse HRP-DAB cell and tissue staining kit in line with the 
manufacturer’s instruction (Abcam). Briefly, sections were blocked with peroxidase blocking 
buffer, followed by serum, avidin, and biotin blocking buffer. Tissue sections were then 
incubated with rabbit anti-mouse CD11b (see section 2.1.8) antibodies overnight at 4°C. 
CD11b is protein expressed on the surface of monocytes and CD11b antibody was used to 
detect the monocytes in pancreas, liver and spleen. Subsequently tissue sections were washed 
and incubated with biotinylated anti-rabbit secondary antibody for 30min at room temperature. 
After washing, the sections were incubated with horseradish peroxidase (HRP)-conjugated 
high sensitivity streptavidin (HSS) for 20min at room temperature followed by incubation with 
freshly prepared 3, 3’-diaminobenzidine (DAB). The sections were counterstained with 
hematoxylin and subsequently dehydrated, mounted, and covered with coverslips.  
 
2.2.4.4 SiRNA transfection 
SiRNA transfection was performed with different siRNA concentrations and transfection times 
to determine the most efficient dose of siRNA by which to silence the CSE gene. In vivo 
transfection of siRNA was performed using the invivofectamin kit (Invitrogen) as per the 
manufacturer’s instruction. Briefly, 7mg/kg of siRNA was diluted in a complexation buffer to 
make a 100µl solution and mixed with 100µl of invivofectamin, vortexed and centrifuged. The 
solution was heated for 30 minutes at 50°C. Dialysis was performed for 2h in 1L sterile PBS 
to desalt the solution using a Float-A-Lyzer before injection (See section 2.2.26). Tail vein 
injection was performed using 200µl of the prepared solution. 
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2.2.5 Statistical analysis 
Prism Graphpad 6 (GraphPad Software Incorporated, La Jolla, CA, USA) was used for 
statistical analyses of the results. ANOVA table is presented as F (DFn, DFd). Dfn is the degree 
of freedom for the numerator of the F ratio, and DFd is for the denominator. Data are expressed 
as mean ± standard deviation. Differences between two groups of data were analysed using an 
independent t-test. One way ANOVA with post hoc Tukey’s test was performed to compare 
multiple groups using GraphPad version 6. Two way ANOVA with post hoc Sidak’s test was 
used to examine the effect of two different independent variables on one continues dependent 
variable. A p<0.05 was considered statistically significant. All p values between 0.01 and 0.05 
are shown with one (*) asterisk (significant), p values between 0.01 and 0.001 are shown with 
two (**) asterisks (very significant), p value between 0.001 and 0.0001 are designated with 
three (***) asterisks (extremely significant) and p values less than 0.0001 are shown with four 
(****) asterisks (extremely significant).  
 
2.2.6  Appendices: solutions 
1% agarose gel:  1g of agarose was dissolved in 100ml TAE buffer and microwaved for 20-
30 seconds. The solution was left to cool down before adding Sybersafe (1:1000). The agarose 
was poured in the tray with a well comb in place.  
10% stacking gel: to prepare one 10% stacking gel, 1.67ml of 30% Acrylamide:Bisacrylamide 
solution was added to a mixture of 1.25ml Tris HCl buffer (1.5M, pH 8.8), 2ml ultrapure water, 
50µl of 10% (w/v) ammonium persulphate solution and 50µl of 10% (w/v) SDS. 5µl of 
NNN’N’-tetramethylethylenediamine (TEMED) was added immediately prior to pouring the 
gel to initiate polymerization.  
54 
  Chapter 2 
5% resolving gel: to prepare one 5% resolving gels, 0.83ml of 30% Acrylamide:Bisacrylamide 
solution was added to a mixture of 0.63ml of Tris HCl buffer (1M, pH 6.8), 3.4ml ultrapure 
water, 50µl of 10% (w/v) ammonium persulphate solution, 50µl of 10% (w/v) SDS. 5µl of 
TEMED was added immediately prior to pouring the gel to initiate polymerization.  
1.5 M Tris, pH 6.8 (stock buffer for stacking gels): 181.65g Tris base was dissolved in 700 
mL of ultrapure water and pH was adjusted to 6.8 with HCl. The volume was adjusted to1L 
with ultrapure water (The solution should be cool down to room temperature before making 
the final pH adjustment).  
1.5 M Tris, pH 8.8 (stock buffer for separating gels): 181.65g Tris base was dissolved in 
700 mL of ultrapure water and pH was adjusted to 6.8 with HCl. The volume was adjusted 
to1L with ultrapure water (The solution should be cool down to room temperature before 
making the final pH adjustment).  
3× protein loading buffer: To make 10ml stock, 0.4g of sodium dodecyl sulphate (SDS) was 
dissolved in 2.4ml of 1M Tris solution (pH adjusted to 6.8 with HCl). Three ml of glycerol and 
0.006g of bromophenol blue were added and stirred to dissolve before the addition of 1.6ml of 
2-Mercaptoethanol. The resultant buffer was dispensed into 1ml aliquots and stored at –20oC 
until required.  
PBS (stock): a 10× stock solution was made by dissolving 80g sodium chloride, 2g potassium 
chloride, 28.42g di-sodium hydrogen phosphate, and 2g potassium dihydrogen phosphate in 
1L ultrapure water.  
TBS 10×: a stock solution was made up by mixing 24.4g of Tris base and 80g of the sodium 
chloride in 900mL ultrapure water, pH was adjusted to 7.6 with hydrochloric acid and volume 
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adjusted to 1L with ultrapure water. This solution was diluted 1:10 in ultrapure water, as 
required. 
TBST: 100ml of TBS (10×) was added to 1ml of Tween and the volume adjusted to 1l with 
ultrapure water.  
TAE 10×: a stock solution was made by adding 48.44g Tris base in 300 in 120ml ultrapure 
water and adding 11.42ml glacial acetic acid and 0.1M EDTA and volume was adjusted to 
1000ml.  
Transfer buffer10×: a stock solution was made up by dissolving 30.2g of Tris base, 144.45g 
of glycine up to 1l with ultrapure water. To obtain a working solution, 50ml of stock solution 
and 50ml methanol were mixed with 400ml water. 
Transfer buffer (working): a 1× working solution was made by adding 100ml of transfer 
buffer stock to 800ml ultrapure water supplemented with 100ml methanol (stored in 4°C 
Float-A-Lyzer for dialysis in vivo siRNA: the device was filled with 10% ethanol and left in 
room temperature for 10min. Ethanol was aspirated out and was replaced with sterile distilled 
water for 20min. The device was inverted and shaken out for any remaining drops. 
Sodium phosphate buffer (PH7.4): a mixture of NaH2PO4 (77.4ml) and Na2HPO4  (22.6ml) 
was prepared and the pH was adjusted to 7.4. 
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Inflammation is a multi-step process in the body in response to stimuli and activated immune 
cells, such as macrophages, play an important role in mediating this process [293]. During the 
inflammatory response, monocytes migrate to the site of inflammation and differentiate into 
macrophages. Macrophages play a crucial role in the immune response to different stimuli and 
are considered major contributors to the inflammatory response by generation of pro-
inflammatory (IL-6, IL-1β, and TNF-α) and anti-inflammatory (IL-10) cytokines [294-296]. 
Despite the essential role of recruited macrophages during inflammation, controlled activation 
of these cells is a vital part of host defence as macrophages can play a key role in tissue damage 
and any consequential resulting functional loss through the extended release of pro-
inflammatory cytokines [297, 298].  
Hydrogen sulfide is the third gaseous transmitter molecule together with NO and CO [299]. As 
discussed in Chapter 1, H2S is involved in a wide range of physiological functions and plays a 
key role in inflammation [300]. In this thesis, I have studied the role of CSE in inflammation 
by inhibiting CSE expression through gene silencing. This is examined later in chapters 4 and 
5. Elevated levels of CSE expression and H2S production by LPS-induced macrophages have 
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3.1.1 Objectives 
 
 To confirm that the CSE gene and protein are expressed in RAW 264.7 cells. 
 To demonstrate the up-regulation of the CSE gene in RAW 264.7 cells following 
activation with LPS. 
 To examine CBS gene expression in RAW 264.7 cells.  
 To determine the optimum experimental parameters for LPS stimulation and 
inflammatory cytokine expression for subsequent experiments. 
 To determine the levels of inflammatory cytokines and NO released by LPS-activated 
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3.2 Results 
3.2.1 Morphological changes of LPS-treated RAW 264.7 cells 
Resting RAW264.7 cells showed a typical spherical shape; indicative of its quiescent state, 
(Figure 3-1 A). However, cells activated with LPS became larger and irregular form which 




Figure 3-1. Morphological alteration in RAW 264.7 cells following treatment with LPS. Morphology of RAW 
264.7 cell visualized by light microscopy. The cells were pre-treated with LPS for 6h (B) showed an irregular 
shape compared to untreated cells (A). Scale bar is 200µm. 
 
3.2.2 CSE gene expression in RAW 264.7 cells 
RAW 264.7 cells were seeded in 6 well plates. The cells were treated with LPS when 60-70% 
confluent. The size of LPS-treated RAW 264.7 cells increased and acquired a distinct dendritic 
morphology. To assess the effect of activation through LPS treatment on CSE and CBS mRNA 
levels, 24 hours after treating the cells with 1ug/ml LPS, the RNA was extracted, converted to 
cDNA and amplified using PCR. Following electrophoresis there was a single band for the 
CSE gene present but bands for CBS were not detected (Figure 3-2). 
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Figure 3-2. RT-PCR analyses for CSE and CBS genes in RAW 264.7 cells. Cells treated with 1ug/ml LPS for 
24 hours. Total RNA was extracted and converted to cDNA. Beta actin was used as a house keeping gene to 
determine CSE and CBS gene expression. (A) Expression levels of CSE in untreated and LPS-treated RAW 
264.7 cells (B) Housekeeping gene expression levels (beta actin). (C) CBS gene expression was not detected in 
RAW 264.7 cells.  
 
3.2.3 Quantitative PCR for CSE expression in LPS-treated RAW 264.7 cells 
Quantitative PCR was then conducted to compare the levels of the expression of the CSE gene 
in the absence or presence of LPS. The results showed that following treatment of RAW 264.7 
cells with LPS (1µ/ml) for 24 hours, the expression of CSE mRNA increased 5-6 fold compared 
to untreated cells (Figure 3-3). 
 
 
Figure 3-3. QPCR analysis in LPS-treated RAW 264.7 cells. Cells were seeded in 6 well plates and treated with 
1µg/ml LPS for 24 hours. Total RNA was extracted and converted to cDNA to run qPCR. Data were normalised 
with β-actin as a housekeeping gene and expressed as fold increase over control. The level of mRNA expression 
for CSE in LPS-treated cells was higher than untreated cells. Results are shown as the mean ± SD. (t-test **, 
p<0.01 compared to control). (n=3). 
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3.2.4 CSE protein expression in LPS-treated RAW 264.7 cells 
Western blot analysis showed a single protein band of approximately 43 kDa corresponding to 
CSE protein was found (Figure 3-4 A). Increased levels of CSE protein expression was 
observed in LPS-treated macrophages compared to untreated cells. CSE protein is over-
expressed in murine liver tissue. Therefore, as positive and negative controls, homogenised 
samples from wild type (WT) and CSE knock-out (KO) mice liver tissue were used to confirm 
protein expression by these cells. HPRT was used as a house keeping as a loading control.  
 
 
                      
 
 
Figure 3-4. Western blot analysis of CSE expression in untreated and LPS treated RAW 264.7 cells and liver 
tissue from WT and CSE KO mice. (A) CSE protein levels, with LPS treated RAW 264.7 cells had higher levels 
of CSE protein. The results were confirmed with liver samples from CSE knockout (KO) (no band) and wild type 
mouse (strong CSE band) (WT). (B) Housekeeping protein levels in all samples (HPRT). Blot is representative 
of three different experiments. 
 
3.2.5 The effects of LPS on cytokines secretion in LPS-treated RAW 264.7 cells 
To establish the best concentration of LPS needed to activate the RAW 264.7 cells and at the 
time after LPS treatment that activation occurs, an experiment was performed in which LPS 
was administered at 5 different concentrations and the levels of secreted cytokines were 
measured at 6 hours and 24 hours after administration. At these time points the media was 
removed and, using an ELISA assay, analysed for secreted TNFα, IL-6, IL-1β and MCP-1.  
 
KO WT Untreated LPS 
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3.2.5.1 TNF-α 
TNF-α levels in growth media were measured using an ELISA assay. Concentrations of 1-
1000ng/ml LPS significantly increased TNF-α production at both time points (Two-way 
ANOVA, p<0.0001) (Figure 3-5). There was also a significant difference between LPS 
concentration and TNF-α productions at the two time points when 100 ng/ml and 1000 ng/ml 
were used (Two-way ANOVA, p<0.0001). As 100 ng/ml of LPS gave a robust significant 
increase in TNF-α production this concentration of LPS was used in all further experiments. 
Higher levels of TNF-α were consistently measured at 24 hours compared to 6 hours, 
suggesting that activation is continuing after the 6 hours time point and TNF-α is accumulating 
in the growth media (Figure 3-5). These results demonstrated that an LPS concentration of 
100ng/ml at the time point of 24 hours should give the right balance of moderate activation of 
the cells and detectability of the TNF-α when investigating the effects of CSE inhibiting siRNA 
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Figure 3-5. The effects of LPS concentration on TNF-α secretion by RAW 264.7 cells at 6 hours and 24 hours 
after LPS administration. Supernatant was collected after 6h and 24h treatment with LPS and the levels of TNF-
α was measured using an ELISA. The results are shown as the mean ± SD. The significance of difference among 
the groups was evaluated by two way ANOVA with a post hoc Sidak’s test for multiple comparisons. There was 
a significant increase in the levels of TNF-α with increased dose of LPS (100-1000ng) in two times point, two-
way ANOVA, ****= p<0.0001. (n=3).   
 
3.2.5.2 IL-6 
ELISA analysis was performed to determine the levels of IL-6 in the supernatant of the cultured 
RAW 264.7 cells. The highest levels of IL-6 were found 24 hours after stimulation with 100 
ng/ml of LPS (Figure 3-6). The highest concentration of LPS (1000 ng/ml) did not induce more 
IL-6 production compared to the lower LPS concentrations at 24 hours but it induced higher 
levels of IL-6 production at the 6 hours time point (Figure 3-6). The IL-6 levels increased at 
24 hours with LPS dose up to 100ng/ml but it reduced between 100 ng/ml and 1000 ng/ml LPS 
at this time. There was a significant difference between the LPS concentration and IL-6 levels 
at the two time points when 100 ng/ml was used (two-way ANOVA, p<0.001). The 
concentration of IL-6 increased at 24 hours with LPS dose up to 100 ng/ml but there was a 
significant drop between 100 ng/ml and 1000 ng/ml LPS at this time (one-way ANOVA, 
p<0.05). Taken together these results suggest that like TNF-α, IL-6 secretion with 100 ng/ml 
LPS is continuing after the 6h time point and is accumulating in the growth media (Figure 3-
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6). These results demonstrate that an LPS concentration of 100 ng/ml at the time point of 24 
hours should give the right balance of moderate activation of the cells and detectability of IL-
6 when investigating the effects of CSE inhibiting siRNA on IL-6 production in RAW 264.7 
cells (see Chapter 4).  
 
 
Figure 3-6. The effect of LPS concentration on IL-6 secretion by RAW 264.7 cells at 6h and 24 hours after LPS 
administration. Supernatant was collected after 6h and 24h treatment with LPS and the levels of IL-6 were 
measured using an ELISA. Results are shown the mean ± SD. The significance of difference among groups was 
evaluated by a two-way ANOVA with a post hoc Sidak’s test for multiple comparisons and one way ANOVA 
with a post hoc Tukey’s test for multiple comparisons. There were significant differences between two time point 
when 100ng/ml LPS was used, two way ANOVA, ***=p<0.001. There was also a significant drop between 100 
ng/ml and 1000 ng/ml LPS at the 24 hours point (One-way ANOVA, p<0.05). (n=3). 
 
3.2.5.3 IL-1β 
The levels of IL-1β in the supernatant of RAW cells stimulated by LPS were measured using 
an ELISA. The highest level of IL-1β was found 6 hours after the addition of 1000 ng/ml of 
LPS to the cells (Figure3-7). The highest concentration of LPS (1000 ng/ml) did not induce 
more IL1-β production after 24 hours compared to 6 hours. The highest amount of IL-1β 
production by RAW cells with 24 hours treatment achieved when they were treated with 10 
ng/ml for 24 hours (Figure 3-7). The concentration of IL-1β increased at 24 hours with the LPS 
dose up to 10 ng/ml but there was a significant drop between 10 ng/ml and 100-1000 ng/ml 
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LPS at this time (one-way ANOVA, p<0.01). There was a significant difference between the 
LPS concentration and IL-1β production at the two time points when 10 ng/ml and 1000 ng/ml 
were used (two-way ANOVA, p<0.001).  
Although 10 ng/ml of LPS gave a significant increase in IL-1β levels at the 24 hours time point 
100 ng/ml of LPS was used in all further experiments so that the same dose of LPS could be 
used in subsequent experiments when all cytokines were measured. More IL-1β was 
consistently measured at 6 hours compared to 24 hours, suggesting that activation is not 
continuing after the 6 hours time point and IL-1β is not accumulating in the growth media 
(Figure 3-7).  
 
 
Figure 3-7. The effects of LPS concentration on IL-1β production by RAW 264.7 cells after 6h and 24 hours LPS 
treatment. The supernatant was collected after 6h and 24h treatment with LPS and the levels of IL-1β was 
measured using an ELISA. The results are shown the mean ± SD. The significance of difference among groups 
was evaluated by two-way ANOVA with a post hoc Sidak’s test for multiple comparisons and one way ANOVA 
with a post hoc Tukey’s test for multiple comparisons. There was a significant difference in IL-1β levels in 
10ng/ml and 100-1000 ng/ml when cells were treated for 24h, (one-way ANOVA, **=p<0.01. There was also a 
significant difference in IL-1β levels between the two time points when 10 and 1000ng LPS was used, two way 
ANOVA, ***= p<0.001. (n=3).  
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3.2.5.4 MCP-1 
The chemokine MCP-1 was also investigated for LPS induced secretion with an ELISA.  There 
was a significant effect of LPS concentrations (Two-way ANOVA, p<0.001) on MCP-1 levels 
in the supernatant. There was also a significant difference between LPS concentration and 
MCP-1 production at the two time points when 10ng/ml, 100 ng/ml and 1000 ng/ml were used 
(two-way ANOVA, p<0.02). There was also significant difference in the interaction between 
LPS concentration and MCP-1 production between the two time points (two-way ANOVA, 
p<0.01). The highest concentration of LPS (1000 µg/ml) did not induce more MCP-1 levels 
compared to lower LPS concentrations at the 24h time point but it induced higher levels of 
MCP-1 at the 6h time point (Figure 3-8). The 24 hours time point treated with 1000 ng/ml LPS 
did not induce more MCP-1 production compared to 100 ng/ml treatment. Increasing the 
concentration of LPS resulted in a lower level of MCP-1 at the 24h time point and higher levels 
of MCP-1 at the 6 hours time point (figure 3-8). The concentration of MCP-1 increased at the 
24 hours with LPS doses of 10, 100 and 1000 ng/ml compared to untreated cells (One-way 
ANOVA, p<0.01). Administration of 10-100 ng/ml LPS to the RAW cells at the time point of 
24h should give the right balance of moderate activation of the cells and detectability of MCP-
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Figure 3-8. The effects of LPS concentration on MCP-1 production by RAW 264.7 cells after 6 hours and 24 
hours LPS treatment. The supernatant was collected after 6h and 24h treatment with LPS and the levels of MCP-
1 were measured using an ELISA. The significance of difference among groups was evaluated by two-way 
ANOVA with a post hoc Sidak’s test for multiple comparisons and one way ANOVA with a post hoc Tukey’s 
test for multiple comparisons. There were significant differences in MCP-1 levels at the two time points 6h and 
24h, two-way NAOVA **=p<0.01. There were also significant differences in MCP-1 levels in two time points 
when cells were treated with 10, 100 and 1000ng/ml LPS, two-way ANOVA * = p<0.02. Treatment with 10-
100ng/ml LPS increased the levels of MCP-1 significantly at the 24 houre time point compared to untreated cells 
(one way-ANOVA, **=p<0.01). (n=3). 
 
3.2.6 NO production in LPS-induced RAW 264.7 cells 
To determine the level of Nitric oxide accumulation in the supernatant,  RAW 264.7 cells were 
treated with increasing doses of LPS (1,10,100,1000 ng/ml) and incubated for 6 and 24 hours 
before harvesting. The supernatant was collected for NO analysis using the Griess assay 
(Chapter 2, section 2.2.10). The results showed that LPS induced NO production was both dose 
and time dependent (two-way ANOVA, p<0.0001 and two-way ANOVA, p<0.0001 
respectively). However, after 6h treatment the NO levels in untreated cells were higher than 
the cells treated with 1ng/ml, 10 ng/ml and 100 ng/ml of LPS and treatment of RAW 264.7 
cells with LPS did not increase NO levels. The difference in the interaction between LPS 
concentration and NO levels between the two time points was also significant (two-way 
ANOVA, p<0.0001). RAW cells activated with 1000 ng/ml LPS produced the highest level of 
NO (Two-way ANOVA, p<0.0001). The supernatant at the 24h time point had higher levels of 
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NO at all LPS concentrations, meaning there was continued activation and also accumulation 
of NO in the growth media after the 6 hours time point (Figure 3-9). The concentration of NO 
increased at 24 hours with the LPS dose and there was a significant increase between 0-1000 
ng/ml LPS at this time (one-way ANOVA, p<0.001). These findings suggested that to study 
the effect of CSE targeting siRNA on NO production, an LPS concentration of 10-100 ng/ml 
at the time point of 24 hours should give a good balance of moderate activation of RAW cells 
and detectability of NO. 
 
 
Figure 3-9. The effect of LPS concentration on the NO production by RAW 264.7 cells following treatment cells 
with LPS for 6 hours and 24 hours. The significance of difference among groups was evaluated by two-way 
ANOVA with a post hoc Sidak’s test for multiple comparisons and one way ANOVA with a post hoc Tukey’s 
test for multiple comparisons. The supernatant was collected and NO was measured using the Griess assay. The 
results are shown as the mean ± SD. There were no significant differences in NO levels with 6h treatment. 24h 
treatment was significantly different from the 6h group using a two-way ANOVA ***= p<0.0001. There was a 
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3.3 Discussion 
Macrophages play a key role in expression of pro-inflammatory cytokines and proteins via pro-
inflammatory signal transduction cascades and because of this, these cells are thought to have 
a crucial role in the inflammatory response [302]. Activated macrophages secrete high levels 
of cytokines, such as TNF-α, IL-1β and IL-6  [118, 303, 304] which have been shown to play 
important roles in pro-inflammatory responses. In agreement with previous reports, results 
from these experiments confirmed that the pro-inflammatory cytokines TNF-α, IL-1β, IL-6, 
and MCP-1 are produced by RAW 264.7 cells following stimulation with LPS.  
LPS is a major component of the outer memberane of gram-negative bacteria and is strong 
inducer of the systemic inflammatory response [305]. An in vitro study of LPS-induced RAW 
264.7 cells reported by Ming Lei et al [306], showed that the time of exposure and also the 
concentration of LPS, determined the levels of pro-inflammatory mediators produced by 
activated cells. In this set of experiments the time and concentration of LPS on the levels of 
inflammatory cytokines produced by macrophages were examined. Exposure of cells to 
different concentrations of LPS (0-1000 ng/ml) revealed that the levels of IL-6 and MCP-1 
reached a peak after 24 hours when treated with 100 ng/ml LPS while Il-1β and TNF-α release 
after 24 hours was maximal with 10 ng/ml and 1000 ng/ml, respectively. The time of activation 
was the second variable examined in activation of cells with LPS. The results showed that the 
highest level of TNF-α, IL-6, and MCP-1 produced by the cells occurred when cells were 
exposed to LPS for 24 hours while for IL-6 the highest levels were observed at 6 hours. 
Therefore, 100 ng/ml for 24 hours was selected as the concentration and time of exposure to 
activate RAW 264.7 cells. LPS was dissolved in sterile PBS and there is no report of biological 
effects of PBS on RAW 264.7 cells. Therefore control cells were not treated with PBS.  
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In accordance with a previous report [182], the set of experiments demonstrated that RAW 
264.7 cells express CSE mRNA and activation of these cells with LPS resulted in increased 
expression of CSE mRNA and protein but not CBS. CSE protein is highly expressed in liver 
tissue (43KD). Therfore, liver samples were used to confirm the CSE protein expression by 
RAW 264.7 cells. Macrophages express CSE and the level of CSE gene expression increased 
markedly following activation of these cells [307, 308]. H2S is mainly produced by the activity 
of CSE enzyme in macrophages and an increased level of hydrogen sulfide is reported in LPS-
treated macrophages [307, 308]. 
Three isoforms of NOS are endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible 
NOS (iNOS) [309]. Macrophages display a vigorous response to stimuli and produce 
inflammatory mediators such as cytokines and NO [186]. NO was reported to regulate 
inflammatory mediator release by macrophages during inflammation resulting in both anti- and 
pro-inflammatory effects [310]. Elevated levels of iNOS have been observed during 
inflammation that results in a large production of NO by macrophages [186, 311]. The results 
reported in this chapter also confirmed this observation as increased levels of NO produced by 
RAW 264.7 cells were measured following activation of these cells with LPS. The results in 
this chapter confirmed previous reports that CSE is expressed by macrophages and up-
regulated following activation by LPS. In addition LPS-induced macrophages released 
inflammatory mediators including cytokines and NO.  
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4 Silencing CSE gene in LPS-activated RAW 264.7 cells by siRNA 
 
4.1 Introduction 
Although the production of inflammatory cytokines in response to infection may help with the 
elimination of pathogens, uncontrolled production of inflammatory cytokines could result in 
SIRS and tissue damage [312, 313]. Therefore, therapeutic interventions to regulate the 
production of inflammatory mediators may have beneficial effects. H2S is generated by 
macrophages through the activity of the CSE enzyme. It has been shown to function as a 
mediator of the inflammatory response. H2S has a pro-inflammatory effect on macrophages 
may cause lung damage in an experimental model [199, 314]. Inhibition of H2S production 
using PAG showed an anti-inflammatory effect and attenuated organ damage in inflammatory 
diseases, including acute pancreatitis, septic shock, and endotoxemia [1, 199, 242]. A study of 
an animal model of acute pancreatitis also revealed that inhibition of H2S biosynthesis down-
regulated chemokine expression and attenuated disease severity [315]. 
Although inhibition of H2S production with PAG showed promising results, interpretation is 
not absolutely clear because of specificity issues. RNA interference (RNAi) therapeutics, with 
siRNA, could mediate specific knockdown of CSE at the transcriptional level and would be 
greatly beneficial to our understanding of the role of CSE in normal and pathological 
physiology.  
Extracellular signals connect to the nuclear transcriptional machinery via MAPKs. Three 
protein kinases are involved in the MAPK pathway: ERK1/2, JNK, and p38 MAPKs [316, 
317]. The MAPK family consists of three subfamilies which are actively involved in regulation 
of multiple cellular processes, such as gene expression and cell death [318, 319]. LPS has been 
shown to activate the MAPK signalling pathway in mammalian cells [320]. Activation and 
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phosphorylation of ERK1/2, p38MAPK, and JNK have been demonstrated to occur following 
activation with LPS [307, 321]. MAPKs play an important role in cell growth, stress induced 
gene expression and differentiation [322, 323] and regulation of the inflammatory response in 
macrophages [324]. Increased activity of ERK1/2 resulted in production of TNF-α and 
regulated transfer of TNF-α mRNA from the nucleus to the cytoplasm [325]. 
NF-κB regulates many genes that are involved in the immune response. An animal model of 
acute pancreatitis revealed that NF-κB activation led to up-regulation of cytokines [136]. 
Hydrogen sulfide has been shown to exhibit its pro-inflammatory effect via NF-κB and the 
ERK pathway [314]. Increased activity of NF-κB and ERK in hydrogen sulfide-treated 
monocytes resulted in increased levels of pro-inflammatory mediators [314]. In this set of 
experiments siRNA was used to silence expression of CSE by macrophages and examined the 
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4.1.1 Objectives 
 
 To silence CSE gene and protein expression with siRNA in macrophages. 
 To determine the levels of inflammatory cytokines produced by RAW 264.7 
cells following silencing of CSE by siRNA.  
 To determine the role of CSE on the expression of iNOS.  
 To determine the levels of NO production by RAW 264.7 cells following 
silencing of CSE by siRNA. 
 To examine the effect of siRNA on NF-κB activity in LPS-induced RAW 264.7 
cells. 
 To assess the effect of siRNA targeting CSE on the phosphorylation of MAPKs 
in LPS-induced RAW 264.7 cells. 
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4.2 Results 
4.2.1 Optimization of siRNA transfection 
To determine whether it is possible to transfer nanoparticles into mouse monocytes, Block-iT 
Alexa Fluor Red Fluorescent control was used. Block-iT Alexa Fluor is a fluorescent dye which 
is used to indicate transfection efficiency of lipid-based nanoparticles. Cells were incubated 
with different concentrations of the dye (10 or 50nM). Transfection efficiency was higher when 
50nM of Block-iT Alexa Flour was used (Figure 4-1).     
 
  
10nM Alexa Flour 
  
50nM Alexa Flour 
 
Figure 4-1. Block-iT AlexaFluor uptake by RAW 264.7 cells. (A) Cells were incubated with 10nM Block-iT 
AlexaFluor for 24h. (B and D) Cells before incubating with the dye. (C) Cells were incubated with 50nM dye for 
24h. Higher uptake was achieved with 50nM of Block-iT Alexa.  
To optimize the transfection of siRNA into RAW 264.7 cells, several different siRNA 
concentrations and cell densities were assessed. SiRNA was added to 6-well plates (50 nM) 
before seeding with Raw 264.7 cells (2.7×105/well). When cells were seeded at 2x105/well, 
there was insufficient RNA for analysis without incubation for several days. Hence, 7×105 
cells/well was used and this cell density yielded enough RNA for qPCR after incubation 
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overnight in media containing serum without antibiotics (recommended by Ambion). After 
preparation of the wells, siRNA was added, the cells were incubated in serum free media 
overnight and the following day media was replaced with fresh standard media (DMEM) 
containing FCS (10%) and antibiotics (1% penicillin-streptomycin). Cells were then treated 
with LPS (100ng/ml) for 24 hours. QPCR showed that LPS treatment for 24 hours increased 
the levels of CSE expression 5.12 (1.06SD) fold higher than control (one-way ANOVA, 
p<0.001) (Figure 4-2). Analysis by qPCR showed a step wise decrease in CSE gene expression 
with increasing amounts of siRNA (Figure 4-2). SiRNA administration (10nM) inhibited the 
LPS-induced up-regulation of CSE expression with levels 4.59 (0.97 SD) fold higher than 
control (One-way ANOVA, p<0.01) (Figure 4-2) and 30nM of siRNA inhibited LPS-induced 
up-regulation of CSE expression with levels 3.28 (0.40 SD) fold higher than control (one-way 
ANOVA, p<0.05) (Figure 4-2). However, 50nM siRNA inhibited LPS-induced up-regulation 
of CSE gene expression with levels only 1.26 (0.23 SD) fold higher than control (one-way 
ANOVA, p<0.001) (Figure 4-2). These results showed that 50nM siRNA completely silenced 
CSE expression in LPS-treated cells. Therefore, cells were transfected with 50nM of siRNA in 
all subsequent experiments.  
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Figure 4-2. The effects of LPS and siRNA on CSE mRNA expression in RAW 264.7 macrophages. The control 
group was left untreated, the LPS group was incubated with 100ng/L LPS 24 hours prior to qPCR, the LPS + 
siRNA group received 10, 30, and 50nM siRNA 24 hours prior to LPS treatment which was administered 24h 
prior to qPCR. The total RNA was extracted from cells and converted to cDNA to run qPCR. The results showed 
that 10nM siRNA reduced CSE expression compared to LPS-treated cells and 30nM siRNA silenced CSE 
expression significantly compared to LPS group, but 50nM siRNA silenced CSE expression in LPS-treated cells 
completely. CSE mRNA expression was normalised with beta actin gene and expressed as fold control. Results 
are shown as the mean ± SD. The significance of difference among groups was evaluated by ANOVA with a post 
hoc Tukey’s test for multiple comparisons, ***=p<0.001 **=p<0.01 and *=p<0.05. (n=3 per group). 
 
4.2.1.1 Cell viability assay 
The MTT assay was used to assess the toxicity effects of the siRNA on the RAW 264.7 cells. 
The result of the MTT assay showed that 50nM of siRNA was not cytotoxic. Cell viability for 
siRNA transfected cells was 84% of control (non-transfected cells).  
 
4.2.2 Inhibition of CSE mRNA and protein expression by siRNA 
Real time quantitative RT-PCR was performed to quantify CSE transcription in LPS-induced 
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had a significant effect on CSE expression in RAW 264.7 macrophages (F (2, 6) =27.76, 
p<0.001) (Figure 4-3). LPS treatment 24 hours prior to qPCR resulted in a significantly higher 
level of CSE expression with levels 4.8 (1.2SD) fold higher than control (one-way ANOVA, 
p<0.01) (Figure 4-3). SiRNA administration inhibited the LPS-induced up-regulation of CSE 
expression with levels only 1.2 (0.08 SD) fold higher than control (one-way ANOVA, p<0.01) 
(Figure 4-3). Negative siRNA had no effect on LPS-induced up-regulation of CSE gene 
expression. Higher level of the LPS-induced up-regulation of CSE expression with levels of 
4.16 (0.85 SD) fold higher than control was observed in cells pre-treated with negative siRNA 
(one-way ANOVA, p<0.01) (Figure 4-3). 
 
 
Figure 4-3. The effects of LPS and siRNA and negative siRNA on CSE mRNA expression in RAW 264.7 
macrophages. The control group was left untreated, the LPS group was incubated with 100ng/L LPS 24 hours 
prior to qPCR, the LPS + siRNA group received 50nM siRNA, and the LPS + negative siRNA received 50nM 
negative siRNA (scrambled siRNA) 24 hours prior to LPS treatment which was administered 24h prior to qPCR. 
The total RNA was extracted after trypsinization of the cells and then converted to cDNA to perform qPCR. 
SiRNA inhibited LPS-induced CSE expression but there was no effect of negative siRNA on expression of CSE 
in LPS treated cells. CSE gene expression was normalised with beta actin gene expression (housekeeping gene) 
and was expressed as fold control. The results are shown as the mean ± SD. The significance of difference among 
groups was evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons. **=p<0.01. (n=3). 
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To examine the effect of siRNA on CSE protein expression, western blot analysis was 
performed. HPRT was used as the housekeeping gene for protein loading control. A single 
protein band of approximately 43kDa corresponding to the CSE protein was observed. 
RAW264.7 cells treated with LPS expressed higher level of protein (Figure 4-4). The results 
indicated that siRNA targeting of CSE had inhibitory effects on CSE protein expression. 




Figure 4-4. Western blot (A, B, and C) and densitometry (D) analysis of CSE protein expression by RAW 264.7 
cells. LPS-treated cells were incubated with 100ng/ml LPS for 24h. Control cells were untreated. The LPS + 
siRNA group received 50nM siRNA 24 hours prior to LPS treatment which was administered 24h prior to qPCR. 
The LPS + negative siRNA received 50nM negative siRNA (scrambled siRNA) 24 hours prior to LPS treatment 
which was administered 24h prior to qPCR. 24h after treatment with LPS the cells were collected and whole cell 
lysates were examined by western blot using primary antibody against CSE. Equal sample loading was determined 
by internal control HPRT. SiRNA inhibited CSE protein expression in LPS-treated cells. Control cells were 
untreated. Results are shown as the mean ± SD. The significance of difference among groups was evaluated by a 
one way ANOVA with a post hoc Tukey’s test for multiple comparisons. **= p< 0.01 compared to control, LPS 
and siRNA treated groups. (n=3).  
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4.2.3 The effect of siRNA targeting CSE on cytokine secretion by LPS-induced RAW 
264.7 cells 
In the previous chapter the experimental results showed that there was an increased level of the 
cytokine secretion by LPS-treated RAW 264.7 cells (Chapter 3 section 3.2.5). In the following 
set of experiments the effect of siRNA on cytokine secretion and the role of the CSE gene in 
the production of inflammatory mediators was examined. To do this, 24 hours post-transfection 
with siRNA targeting CSE, the cells were treated with LPS (100ng/ml) for 24 hours. The 
supernatant was collected for analysis of IL-6, TNFα, IL-1β and MCP-1 by ELISA. The results 
for these experiments are presented in the follow sub-sections. 
 
4.2.3.1 IL-6 
There was a significant effect of LPS and siRNA treatment on the levels of IL-6 released to the 
supernatant (F (3, 20) = 116.5, p<0.0001) (Figure 4-5). As shown in chapter 3 (section 3.2.5.2), 
the levels of IL-6 increased in LPS-induced RAW 264.7 cells compared to the untreated group. 
Treatment of cells with LPS for 24h demonstrated higher levels of IL-6 production compared 
with the control (mean 75.55 ± 11.53SD) (one-way ANOVA, p<0.0001). Pre-treatment with 
siRNA had a significant inhibitory effect on the levels of IL-6 (mean 13.70 ± 2.8SD) 
(p<0.0001) compared to the cells treated with LPS alone (Figure 4-5). Treatment of cells with 
LPS and negative siRNA had no inhibitory effect on IL-6 production and there were increased 
the levels of IL-6 compared with the control group (mean 71.21 ± 12.19SD) (One-way 
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Figure 4-5. SiRNA against CSE significantly reduced LPS-induced IL-6 production by RAW 264.7 cells. The 
control group is untreated; the LPS group was treated with 100ng/L LPS 24h prior to the ELISA. The siRNA 
group received 50nM siRNA 24 hours prior to LPS treatment which was administered 24 hours prior to ELISA 
assay. The LPS + negative siRNA received 50nM negative siRNA (scrambled siRNA) 24 hours prior to LPS 
treatment which was administered 24h prior to the ELISA. The results are shown as the mean ± SD. The 
significance of difference among groups was evaluated by a one way ANOVA with a post hoc Tukey’s test for 
multiple comparisons. ****= p<0.0001. (n=3).   
 
4.2.3.2 TNF-α 
LPS and siRNA treatment affected the levels of TNF released by RAW 264.7 cells to the 
supernatant significantly (F (3, 44) = 50.63, p<0.0001) (Figure 4-6). LPS treatment 24h prior 
to the ELISA resulted in a significantly higher level of the TNF-α (mean 11.22 ± 3.33SD) 
compared to the control (mean 0.031 ± 0.001SD) (one-way ANOVA, p<0.0001) (Figure 4-6). 
SiRNA administration significantly reduced LPS-induced TNF-α production (mean 7.78 ± 
2.3SD), (p<0.01) (Figure 4-6). Treatment of cells with LPS and negative siRNA had no 
inhibitory effect on TNF-α production and there were increased levels of TNF-α compared 
with the control group (mean 10.78 ± 2.97SD) (one-way ANOVA, p<0.0001) (Figure 4-6).  
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Figure 4-6. SiRNA against CSE significantly reduced LPS-induced TNF-α production by RAW 264.7 cells. The 
control group is untreated; the LPS group was treated with 100ng/L LPS 24h prior to ELISA assay. The siRNA 
group received 50nM siRNA 24 hours prior to LPS treatment which was administered 24 hours prior to ELISA. 
The LPS + negative siRNA group received 50nM negative siRNA (scrambled siRNA) 24 hours prior to LPS 
treatment which was administered 24h prior to the ELISA. Results are shown as the mean ± SD. The significance 
of difference among groups was evaluated by one way ANOVA with a post hoc Tukey’s test for multiple 




The effect of LPS and siRNA on the levels of IL-1β released to the supernatant was significant 
(F (3, 32) = 37.01, p<0.0001) (Figure 4-7).  The levels of IL-1β in the supernatant of LPS-
treated cells (mean 0.33 ± 0.1SD) (one-way ANOVA, p<0.0001) were significantly higher than 
the control group (mean 0.0055 ± 0.0042SD) (Figure 4-7). Administration of siRNA 
significantly reduced the effect of LPS on the levels of IL-1β in the supernatant of RAW264.7 
cells (mean 0.11 ± 0.045SD) (p<0.0001) (Figure 4-7). Treatment of cells with LPS and negative 
siRNA had no significant inhibitory effect on IL-1β production and there were increased levels 
of IL-1β compared with the control group (mean 0.321 ± 0.1SD) (one-way ANOVA, p<0.0001) 
(Figure 4-7).  
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Figure 4-7. SiRNA against CSE significantly reduced LPS-induced IL-1β production by RAW 264.7 cells. The 
control group is untreated; the LPS group was treated with 100ng/L LPS 24h prior to ELISA assay. The siRNA 
group received 50nM siRNA 24 hours prior to LPS treatment which was administered 24 hours prior to the ELISA 
assay. The LPS + negative siRNA group received 50nM negative siRNA (scrambled siRNA) 24 hours prior to 
LPS treatment which was administered 24h prior to ELISA assay. The results are shown as the mean ± SD. The 
significance of difference among groups was evaluated by a one way ANOVA with a post hoc Tukey’s test for 
multiple comparisons. ****=p<0.0001 and *= p<0.05 (n=3). 
 
4.2.3.4 MCP-1 
LPS and siRNA treatment had a significant effect on the levels of MCP-1 (F (3, 32) = 69.43 
p<0.0001) (Figure 4-8). Following incubation of RAW 264.7 cells with LPS for 24 hours the 
levels of MCP-1 in the supernatant were significantly higher (mean 127.7 ± 21SD) compared 
to the control group (1.13 ± 0.38) (one-way ANOVA p<0.0001) (Figure 4-8). Incubation of 
RAW264.7 siRNA pre-treated cells with LPS for 24 hours resulted in significantly lower levels 
of MCP-1 (mean 85.7 ±32.5SD) (p<0.01) compared with that LPS-treated group (Figure 4-8). 
Treatment of cells with LPS and negative siRNA had no significant inhibitory effect on MCP-
1 production and there were increased the levels of MCP-1 compared with the control group 
(mean 129.4 ± 19.5SD) (one-way ANOVA, p<0.0001) (Figure 4-8).  
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Figure 4-8. SiRNA against CSE significantly reduced LPS-induced MCP-1 production by RAW 264.7 cells. The 
control group is untreated; the LPS group was treated with 100ng/L LPS 24h prior to the ELISA assay. The siRNA 
group received 50nM siRNA 24 hours prior to LPS treatment which was administered 24 hours prior to the ELISA 
assay. The LPS + negative siRNA group received 50nM negative siRNA (scrambled siRNA) 24 hours prior to 
LPS treatment which was administered 24h prior to ELISA assay. The results are shown as the mean ± SD. The 
significance of difference among groups was evaluated by a one way ANOVA with a post hoc Tukey’s test for 
multiple comparisons. ****=p<0.0001 and **=p<0.01. (n=3).  
 
4.2.4 Effects of siRNA against CSE on NO production by LPS-treated RAW264.7 cells 
As shown in chapter 3 (section 3.2.6), LPS-induced RAW 264.7 cells produced more NO 
compared to untreated cells. In this experiment 24 hours after transfection with siRNA 
targeting CSE, the cells were then treated with LPS (100 ng/ml). The supernatant was collected 
48 hours post-transfection for NO analysis using the Griess assay (Chapter 2, section 2.2.3.8). 
The results demonstrated a significant effect of LPS and siRNA on NO production in the 
supernatant of RAW 264.7 cells (F (3, 44) =506.8, p<0.0001) (Figure 4-9). RAW 264.7 cells 
treated with LPS also released higher levels of the NO to the growth media with a measured 
concentration of 0.721 µM (0.056 SD) compared to 0.16 µM (00.74) in the control group (One-
way-ANOVA p<0.0001) (Figure 4-9). However, administration of siRNA to the cells resulted 
in higher levels of NO in the growth media with a concentration of mean 0.81 µM (0.051 SD) 
(One-way ANOVA, p<0.01) compared to the LPS group (Figure 4-9). Treatment of cells with 
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Figure 4-9. CSE targeting siRNA effectively increased LPS-induced NOx production by RAW 264.7 cells. The 
control group is untreated, the LPS group was treated with 100ng/L LPS 24h prior to NO assay and 50nM siRNA 
was transfected to the LPS + siRNA group 24 hours prior to LPS treatment which was administered 24 hours prior 
to NO assay. The negative siRNA + LPS group received 50nM of negative siRNA (scrambled siRNA) 24h prior 
to LPS administration which was 24h before NO assay. The results are shown as the mean ± SD. The significance 
of difference among groups was evaluated by a one way ANOVA with a post hoc Tukey’s test for multiple 
comparisons. ****= p< 0.0001 and ** =p< 0.01 (n=3). 
 
4.2.5 Effects of siRNA against CSE on iNOS expression by LPS-treated RAW264.7 cells 
NOx production depends on iNOS expression in RAW 264.7 cells. Real time quantitative RT-
PCR was performed to quantify iNOS expression in LPS-induced RAW 264.7 cells 
untransfected or transfected with siRNA. LPS-treated cells showed increased levels of iNOS 
expression with levels 11.4 (1.06SD) fold higher than the control (one-way ANOVA, 
p<0.0001). There was a significant increase of iNOS expression in RAW264.7 macrophages 
treated with LPS and siRNA (F (3, 8) =108.5, p<0.0001) (Figure 4-10). SiRNA administration 
increased the effect of LPS on iNOS expression with levels 23.2 (1.4SD) fold higher than 
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control (p<0.0001) (Figure 4-10). There was no significant effect of negative siRNA on iNOS 
expression (Figure 4-10). 
 
 
Figure 4-10. The effects of LPS and siRNA on iNOS mRNA expression in RAW264.7 macrophages. iNOS 
mRNA expression is expressed as fold control. The control group is untreated; the LPS group was treated with 
100ng/L LPS 24h prior to qPCR. SiRNA group received 50nM siRNA 24 hours prior to LPS treatment which was 
administered 24 hours prior to qPCR. The LPS + negative siRNA group received 50nM of negative siRNA 
(scrambled siRNA) 24 hours prior to LPS treatment which was administered 24h prior to ELISA. The results are 
shown as the mean ± SD. The significance of difference among groups was evaluated by one way ANOVA with 
a post hoc Tukey’s test for multiple comparisons. ****= p< 0.0001, *** =p< 0.001, and ** =p< 0.01 (n=3). 
 
4.2.6 Inhibition of NF-κB activity by siRNA in RAW 264.7 cells  
The NF-κB pathway is essential for the activation of most inflammatory genes. Analysis by 
the NF-κB DNA binding assay revealed that the level of NF-κB activity in LPS-induced 
(100ng/ml) RAW264.7 cells was significantly higher than untreated control cells by 1.5 
(0.23SD) fold (one-way ANOVA, p<0.01) (Figure 4-11). To examine whether the NF-κB 
signal transduction pathway is involved in LPS-induced CSE expression, RAW 264.7 cells 
were stimulated with LPS following treatment with siRNA. The results showed that the level 
of NF-κB activity in LPS-induced cells pre-treated with siRNA was reduced significantly 
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compared to untreated LPS-activated cells by 0.8 (0.09SD) fold (One-way ANOVA, p<0.001) 
(Figure 4-11).  
 
Figure 4-11. The effect of LPS and siRNA on NF-κB activity. NF-κB activity is expressed as a fold increase over 
control. The control group is untreated, the LPS group received 100ng/ml LPS 24 hours prior to assay, and the 
LPS+ siRNA group received 50 nM siRNA 24h prior to LPS treatment which was administrated 24h prior to 
assay. The LPS+ negative siRNA group received 50nM of negative siRNA (scrambled siRNA) 24h before 
treatment with LPS which was administrated 24 h prior to assay. The cells were trypsinized and nuclear fractions 
were extracted for the NF-κB DNA binding assay. The results are shown as the mean ± SD. The significance of 
difference among groups was evaluated by one way ANOVA with a post hoc Tukey’s test for multiple 
comparisons. ***=p<0.001 and ** =p<0.01. (n=3).  
 
4.2.7 Effect of LPS on the phosphorylation of MAP kinase in RAW 264.7 cells 
The phosphorylation status of MAP kinases in LPS-induced and CSE gene silenced RAW 
264.7 cells was examined. Before the siRNA experiments were performed it was necessary to 
establish at what time after LPS activation the phosphorylation occurred. To elucidate this, an 
experiment was performed whereby LPS was administered at various time periods and cell 
lysates were analysed for phosphorylation of ERK1/2. The results showed that LPS activation 
increased phosphorylation of ERK1/2 and this had occurred within 15 minutes of treating cells 
with LPS and persisted for a further 15 minutes (Figure 4-12 A, B, and C). Densitometry 
analysis was performed to measure the bands observed in the western blot (Figure 4-12 D and 
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Figure 4-12. LPS induced phosphorylation of ERK1/2 in a time-dependent manner. RAW264.7 cells were 
incubated with 100 ng/ml LPS for 0-2 hours. Total cell lysates were examined by western blot with anti-ERK1/2, 
phospho-ERK1/2 (P-ERK) antibodies to detect phosphor-ERK and total-ERK (A, B, and C). The histograms 
represent the optical density of phospho-ERK1 (D) and phospho-ERK2 (E) protein expression relative to ERK1 
and ERK2 respectively expressed as control fold increase. The results are shown as the mean ± SD. The 
significance of difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for multiple 
comparisons. ****=p<0.0001 and **=p<0.01. (n=3). 
 
4.2.8 Effect of CSE targeting siRNA on phosphorylation of MAP kinase in RAW 264.7 
cells 
It was found that phosphorylation of ERK1 MAP kinase reached a peak after 30 minutes 
activation with LPS in macrophages. Using this time point (30 minutes), the effect of CSE 
targeting siRNA on the phosphorylation of ERK MAP kinase was examined. Results showed 
that siRNA targeting CSE inhibited LPS-induced phosphorylation of ERK1 significantly while 
there was no statistically significant effect of siRNA on ERK2 levels (Fig. 4-13).  
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Figure 4-13. The effect of siRNA on the phosphorylation of ERK1/2 in RAW cells macrophages. Cells were 
incubated with 100 ng/ml LPS for 30 minutes. The siRNA group received siRNA or negative siRNA (scrambled 
siRNA) 24h before LPS treatment. The whole cell lysates were examined by western blot using anti-ERK1/2, 
phosphor-ERK1/2 (P-ERK) antibodies to detect phospho-ERK and total-ERK (A, B, and C). The histograms (D 
and E) represent the ratios of the optical density of phosphor-ERK1/2: total ERK1/2 expressed as control fold 
increase. The results are shown as the mean ± SD. The significance of difference among groups was evaluated by 
ANOVA with a post hoc Tukey’s test for multiple comparisons. (One-way ANOVA, ***= p< 0.001 and * =p< 
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4.3 Discussion 
The use of siRNA to silence the CSE gene is an attractive strategy because of the specificity 
and potency of these molecules. In the last few years, siRNA has been intensively studied with 
the hope of developing therapeutic treatments in inflammatory diseases. SiRNA has been 
shown to reduce profound inflammation specifically when it was used in an in vitro study 
against membrane-associated cluster of differentiation antigen 14 (mCD14) [306] and in an in 
vivo study against MCP-1 receptors (CCR2) [101]. To explore the role of H2S in LPS-activated 
RAW 264.7 macrophages, siRNA was used to knockdown the CSE gene which is responsible 
for producing H2S. 
In the set of experiments described in this chapter, it was demonstrated that silencing CSE gene 
expression in macrophages using CSE targeting siRNA could alleviate inflammation by 
reducing the levels of pro-inflammatory cytokines. The silencing of CSE expression in RAW 
264.7 cells resulted in reduced supernatant levels of TNF-α, IL-1β, IL-6 and MCP-1 following 
LPS administration. These results are consistent with reports of inhibition of H2S production 
by PAG in an animal model of acute pancreatitis that resulted in reduced levels of MCP-1 [1, 
315]. The present experiments also showed that inhibition of CSE gene expression is linked to 
the levels of MCP-1 release by RAW 264.7 cells. This suggests that siRNA targeting CSE 
RAW 264.7 cells could have potential for the treatment of inflammatory disorders. Silencing 
of CSE with siRNA resulted in increased levels of NO production in LPS-induced RAW264.7 
cells suggesting that H2S has an inhibitory effect on NO production. The interaction between 
H2S and NO has been reported in several studies. The inhibitory effect of H2S on NO 
production in LPS-induced RAW 264.7 cells was reported by Oh et al. [183]. They showed 
that H2S inhibited NO production through a mechanism that involves HO-1/CO.  
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An in vivo study in rats by Anuar et al. (2006) showed an inhibitory effect of NO on H2S [326]. 
Administration of nitroflurbiprofen, an NO releaser, to rats pre-treated with LPS, resulted in 
decreased CSE mRNA expression and hydrogen sulfide production [326]. A reduction in the 
activity of NF-ĸB has been suggested as a possible mechanism for this effect of NO [327]. On 
the other hand, Zho et al., (2001) reported that NO could induce an increase in enzymatic H2S 
production in vascular tissues [328]. There has only been one study that investigated the effect 
of CSE-targeted siRNA on the levels of NO production. In that study, siRNA against CSE 
reduced H2S production and in consequence NO production by LPS-induced RAW 264.7 cells 
increased [182]. In accordance with this report, the experiments described in this chapter 
showed that silenced CSE expression resulted in increased levels of NO production in LPS-
induced RAW 264.7 cells. NO production in RAW 264.7 cells depends on iNOS expression. 
The experiments also showed that down regulation of CSE expression in RAW cells resulted 
in increased levels of iNOS expression in these cells. Nitric oxide has been shown to play a 
role in the regulation of inflammation. Increased amounts of NO production in the lungs 
following intra-tracheal instillation of LPS resulted in down-regulation of MCP-1 production, 
neutrophil infiltration and lung injury [329]. This experiments suggested that NO has a 
regulatory effect on the inflammation process. NO production increased upon silencing of the 
CSE enzyme and this led to reduced levels of pro-inflammatory cytokines, suggesting that H2S 
has inhibitory effects on NO production. Therefore, silencing CSE gene expression could 
ameliorate inflammation.  
Treatment of macrophages with LPS triggers the activation of various signalling pathways 
among which the MAPK family plays a significant role in inflammation. Phosphorylation of 
ERK increased as early as 15 minutes after LPS treatment and reached a peak at 30 min, which 
was in accordance with previous reports [307, 321, 330]. However, inhibition of H2S 
production by silencing the CSE gene using siRNA in cells treated with LPS for 30 minutes 
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resulted in reduced phosphorylation of ERK. The results revealed that siRNA has inhibitory 
effects on the production of inflammatory mediators through the inhibition of MAP kinase 
ERK1/2phosphorylation.  
Recently, NF-κB has been shown to be involved in TLR4-mediated up-regulation of CSE 
mRNA expression and generation of H2S in LPS-induced macrophages [307]. In accordance 
with that report, results in this chapter also suggest that NF-κB plays a key role in the 
inflammatory response of LPS-induced macrophages. The set of experiments described in this 
chapter also demonstrated that inhibition of CSE gene expression by siRNA resulted in 
decreased NF-κB activation in LPS-induced macrophages and downregulation of 
inflammatory mediators. These findings indicate that inhibition of pro-inflammatory mediator 
production by LPS-induced RAW 264.7 cells may involve transcriptional regulation through 
suppression of NF-κB-DNA binding causing potential interference with nuclear translocation 
of NF-κB.   
It has been shown that H2S activates NF-κB in macrophages [237]. In results consistent with 
this report, it was found that LPS-induced RAW264.7 cells increased the activity of NF-κB, 
and this effect was attenuated by siRNA against CSE. Therefore, H2S induces NF-κB activation 
and acts as a pro-inflammatory mediator in macrophages. The role of NF-κB in activation of 
inflammatory cytokines is well-known. Consequently, NF-κB might be a potential target for 
pharmacological therapy in inflammatory disease.  
In conclusion, the experiments described in this chapter have shown that CSE-targeted siRNA 
inhibited NF-κB activation and ERK phosphorylation in LPS-induced murine macrophages 
and in consequence, down-regulates secretion of pro-inflammatory mediators by LPS-induced 
macrophages. These results showed that CSE mediates activation of macrophages via the ERK- 
NF-κB pathway.   
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Acute pancreatitis is caused by early injury to acinar cells leading to a local, and in severe 
cases, systemic inflammatory response that results in distant organ damage. Dysregulation 
of the immune system plays a key role in the developing infection and organ dysfunction. 
The extreme inflammatory response in severe acute pancreatitis mediates pathological 
damage [331, 332]. Activation of leukocytes results in release of pro-inflammatory 
mediators that are responsible for local pancreatic damage and the development of SIRS and 
MOD in severe acute pancreatitis, which are the primary cause of morbidity and mortality 
in this condition [333, 334]. Activation of macrophages and the levels of activation of these 
cells are thought to play a key role in the severity of acute pancreatitis [335].  
Amylase is an enzyme that catalyses starch. It is mainly produced in the pancreas. Any insult 
to the pancreas can damage the integrity of the acinar cells and release of amylase into the 
blood stream causing hyperamylasemia [336]. The degree of elevation of serum amylase 
levels have been shown to be correlated with the severity of acute pancreatitis severity in 
mice [109]. Determination of the pancreatic amylase level in blood serum is considered as 
an important method in the biochemical diagnosis of pancreatic disorders [337].  
Hydrogen sulfide is a biological mediator that plays an important role in normal physiology 
and disease. Studies in mice have shown that LPS administration results in heightened levels 
of hydrogen sulfide in the plasma as well as up-regulation of CSE mRNA expression in the 
kidney [338]. A potential pro-inflammatory role for hydrogen sulfide in acute pancreatitis 
was reported by Bhatia et al. [1]. Caerulein-treated pancreatic acinar cells showed increased 
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levels of CSE expression and H2S production but decreased levels of CBS expression 
suggesting CSE as the only enzyme involved in H2S production in acinar cells [339]. A 
recent study of a mouse model of acute pancreatitis revealed a key role for CSE in acute 
pancreatitis and deletion of this gene protected the mice against acute pancreatitis and 
associated lung injury [45]. 
Inhibition of hydrogen sulfide production by synthetic drugs, such as PAG, ameliorated 
inflammatory disease while administration of hydrogen sulfide donors exacerbated the 
severity of inflammatory disorders [199, 242, 339]. However, the inhibitory effects of PAG 
on hydrogen sulfide production are not specific. PAG has poor specificity and also plugged 
with limited cell membrane permeability  [340].  
The beneficial effect of inhibiting endogenous hydrogen sulfide production has been 
reported in a number of animal models of inflammatory diseases [165, 338, 341]. An in vivo 
study demonstrated that inhibition of hydrogen sulfide production ameliorated the severity 
of acute pancreatitis and associated lung injury [199]. These reports pointed to an important 
pro-inflammatory role for hydrogen sulfide. Over expression of key pro-inflammatory 
cytokines such as TNF-α, IL-1β and IL-6 regulates cascades of cytokines, chemokines and 
adhesion molecules in many inflammatory disease [342-344].  
RNA interference (RNAi) based technology holds significant promise as an effective 
strategy of the gene therapy that is much more specific than PAG to inhibit hydrogen sulfide 
production. SiRNA has been shown to reduce profound inflammation when it was used in 
an in vivo model of mouse atherosclerosis against MCP-1 receptors [101]. RNAi 
therapeutics, with siRNA, could induce specific knockdown of CSE expression at the 
transcriptional level and greatly benefit our understanding of the role of CSE in acute 
pancreatitis. In the set of experiments described in this chapter, siRNA was used to silence 
                                                                                                                                            93 
  Chapter 5  
expression of CSE by macrophages in a mouse model of acute pancreatitis. Caerulein was 
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5.1.1 Objectives 
 To confirm in vivo delivery of siRNA into blood monocytes after tail vein injection 
in mice. 
 To silence CSE gene expression with siRNA in vivo.  
 To determine the effect of CSE gene silencing on the severity of acute pancreatitis 
in mice (assessed by plasma amylase, pancreas MPO, pancreas histology). 
 To determine the effect of CSE gene silencing on the severity of acute pancreatitis-
associated lung injury (assessed by lung MPO, lung histology). 
 To determine the levels of local inflammatory cytokines and chemokines produced 
in pancreas, lung and plasma in a mouse model of acute pancreatitis following 
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5.2 Results 
5.2.1 In vivo delivery of siRNA into blood monocytes via tail vein injection  
To determined transfection efficiency, immunofluorescent staining was performed on 
the sections from liver and pancreas. The results revealed the presence of fluorescent 
labelled siRNA, Alexa Fluor 647 in liver (Figure 5-1 B) and pancreas (Figure 5-1 D). CD11b 
staining confirmed the presence of the circulating monocytes in the liver (Figure 5-1 A) and 
pancreas (Figure 5-1 C). 
 
Figure 5-1. Fluorescent labelled siRNA detected in the liver of mice. Tail vein injection of fluorescent labelled 
siRNA resulted in detection of Alexa Fluor 647 in the liver (B) and pancreas (D). CD11b staining of the liver 
(A) and pancreas (C) confirmed presence of fluorescent labelled blood monocytes in the liver and pancreas. 
Arrows indicate Alexa Fluor 647 labelled siRNA and monocytes.  
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5.2.2 Infiltration of the leukocytes into the pancreas following induction of acute 
pancreatitis 
Immunofluorescent staining with CD11b staining was performed to confirm infiltration of 
fluorescent labelled siRNA transfected monocytes into the pancreas after the induction of 
acute pancreatitis. Alexa Fluor 647 was detected in the pancreas (Figure 5-2 A) following 
the onset of acute pancreatitis. CD11b staining confirmed leukocyte infiltration in the 
pancreas (Figure 5-2 B), after induction acute pancreatitis. This confirmed fluorescent 
labelled siRNA delivery into the monocytes that had infiltrated into the pancreas (Figure 5-
2 C). These results confirmed in vivo fluorescent labelled siRNA transfection into the 
monocytes following injection into the tail vein.  
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Figure 5-2. Fluorescent labelled siRNA in the pancreas after the induction of acute pancreatitis. Alexa Fluor 
647 was detected in pancreas after induction of acute pancreatitis (A). CD11b staining demonstrated infiltration 
of macrophage and neutrophils into the pancreas after induction of acute pancreatitis (B). The merged image 
(C), confirmed successful transferring of fluorescent labelled siRNA into the blood monocytes which were 
detected in the pancreas. The arrows indicate fluorescent labelled siRNA, monocytes and transfected siRNA 
in the monocytes. 
 
5.2.3 Effect of administration of in vivo siRNA on the expression of CSE 
To examine the effect of in vivo siRNA on CSE protein expression, western blot analysis 
was performed using lung tissue. A single protein band of approximately 43kDa 
corresponding to CSE protein was observed. Lung samples from mice treated with caerulein 
expressed higher levels of protein compared to saline group (Figure 5-3). The results 
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indicated that siRNA targeting CSE had inhibitory effects on CSE protein expression in 
macrophages. SiRNA had no effect on the expression of GAPDH, which was used as loading 
loading control (Figure 5-3).  
 
 
Figure 5-3. Western blot (A, B, and C) and densitometry (D) analysis of CSE protein expression in the lung. 
The saline group considered as control group. Mice were injected hourly with caerulein for 10h. The caerulien 
+ siRNA group pre-treated with siRNA 24h prior to caerulein administration. Total cell lysates were examined 
by western blot with anti-CSE antibody to detect CSE expression. The histograms represent the optical density 
of CSE protein expression relative to GAPDH expressed as control fold increase. Administration of caerulein 
increased CSE protein expression. Reduced expression of CSE in the lung of the mice treated with siRNA was 
determined. The significance of difference among groups was evaluated by ANOVA with a post hoc Tukey’s 
test for multiple comparisons. The esults are shown as the mean ± SD. (One-way ANOVA, **= p< 0.01).  
 
5.2.4 Effect of caerulein-induced acute pancreatitis on pancreas and lung MPO 
activity  
MPO activity in the pancreas and lungs was measured as a marker of neutrophil 
sequestration in these respective organs. The activity of MPO was quantified to determine 
the effect of siRNA silencing of the CSE gene on inflammation of the pancreas and the lung. 
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There was a significant effect of caerulein and siRNA treatment on the levels of pancreatic 
MPO (F (2, 21) = 105.06). Pancreatic MPO activity increased significantly (mean 16.95 ± 
SD 3.22) compared to the saline (1.00 ± 0.79) group (One-way ANOVA, p<0.0001) (Figure 
5-4 A). Silencing the CSE gene with siRNA resulted in a significant decrease in pancreatic 
MPO activity in caerulein-induced acute pancreatitis in mice (mean 3.97 ± SD 2.29) 
compared to caerulein-treated mice (figure 5-4 A). Similarly, treatment of mice with 
caerulein and siRNA showed a significant effect on the levels of lung MPO (F (2, 15) = 
58.50). Lung MPO activity increased following treatment with caerulein (mean 3.71 ± 
0.84SD) compared to the saline control group (mean 1.00 ± 0.45SD) (One-way ANOVA, 
p<0.0001) (Figure 5-4 B). However, MPO levels in the lungs of the caerulein-induced acute 
pancreatitis mice pre-treated with siRNA was markedly reduced (mean 0.84 ± 0.38SD) 
compared to that of the caerulein-induced acute pancreatitis (Figure 5-4 B). 
 
Figure 5-4. Administration siRNA against CSE reduced pancreatic and lung MPO activity. Samples were 
collected from the pancreas and lung tissues from mice given 10 hourly injections of saline or caerulein (50 
µg/kg) or caerulein pre-treated with a single dose of siRNA (7mg/kg/day) 24h prior to caerulein treatment. 
The tissue samples were homogenised and the pellets were used for the MPO assay as described in section 
2.2.21. The results are shown as the mean ± SD for eight mice in each group. The significance of difference 
among groups was evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons. (One-way 
ANOVA, ****= p< 0.0001). 
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5.2.5 Plasma amylase production in caerulein-induced pancreatitis following 
delivery of in vivo siRNA 
There was a significant effect of caerulein and siRNA treatment on the levels of circulating 
plasma amylase activity (F (2, 21) = 37.06) (Figure 5-5). The levels of plasma circulating 
amylase increased following treatment of the animals with caerulein (mean 7465 ± 2285SD) 
compared to the saline group (mean 1256 ± 269.5SD) (One-way ANOVA, p<0.0001). CSE 
gene silencing using siRNA had a significant effect on the levels of circulating plasma 
amylase (mean 5036 ± 1024SD) compared to caerulein-treated group (Figure 5-5). 
 
 
Figure 5-5. CSE gene silencing reduced circulating plasma amylase activity in caerulein-treated mice. Blood 
samples were collected from the pancreas and lung tissues from mice given 10 hourly injections of saline or 
caerulein (50 µg/kg) or caerulein pre-treated with single dose of siRNA (7mg/kg/day) 24h prior to caerulein 
treatment. Plasma was prepared and amylase was performed as described in chapter 2.2.22. Caerulein-treated 
mice showed significantly higher circulating amylase activity compared with saline treated (P<0.0001). 
SiRNA against CSE significantly reduced increased circulating activity of plasma amylase in caerulein-
induced acute pancreatitis. The results are shown as the mean ± SD for eight mice in each group. The 
significance of difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for multiple 
comparisons. (One-way ANOVA, ****= p< 0.0001 and **=p< 0.01). 
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5.2.6 Effect of in vivo siRNA targeting CSE gene on the levels of pro-inflammatory 
mediators increased following caerulin-induced acute pancreatitis  
The results in this chapter showed increased levels of pro-inflammatory cytokines in 
caerulein-induced acute pancreatitis in mice. In this study the effect of siRNA on cytokine 
secretion on the role of CSE gene in the production of inflammatory mediators was 
examined. The results for these experiments are presented as sub-sections below. Eight mice 
were used for each group in this study, however, because of the shortage of the samples 
prepared from the pancreas and lungs ELISA assay was performed for 6 animals only.  
 
5.2.6.1 Pancreatic and lung TNF-α production in caerulein-induced acute 
pancreatitis following delivery of in vivo siRNA 
Caerulein and siRNA treatment had a significant effect on the levels of pancreatic TNF-α 
(F (2, 21) = 57.47 p<0.0001) (One-way ANOVA, p<0.0001) (Figure 5-6 A). There was a 
significant increase in the levels of pancreatic TNF-α in caerulein-induced acute pancreatitis 
mice (mean 67.39 ± 9.52SD) compared to the saline control group (mean 12.34 ± 8.130SD) 
(Figure 5-6 A). Administration of siRNA against H2S synthesising CSE had an inhibitory 
effect on the levels of TNF-α (mean 44.42 ± 12.75SD) compared to controls in caerulein 
treated mice (Figure 5-6 A). 
There was also a significant effect on the lung TNF-α levels in animals treated with caerulein 
and siRNA compared with saline treated controls (F (2, 21) = 46.94 p<0.0001) (One-way 
ANOVA, p<0.0001) (Figure 5-6 B). Caerulein-induced acute pancreatitis increased the 
levels of lung TNF-α (mean 98.70 ± 18.87SD) compared to saline control group (mean 16.91 
± 10.96SD). Silencing H2S synthesising CSE with siRNA resulted in reduced levels of TNF-
α (mean 64.74 ± 19.68SD) compared to the caerulein-treated mice (Figure 5-6 B). 
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Figure 5-6. SiRNA treatment attenuated caerulein-induced increase in the TNF-α production in the pancreas 
(A) and lungs (B). Samples were collected from the pancreas and lung tissues from mice given 10 hourly 
injections of saline or caerulein (50 µg/kg) or caerulein pre-treated with single dose of siRNA (7mg/kg/day) 
24h prior to caerulein treatment. The tissue samples were homogenised and the supernatant was used for the 
ELISA. The absorbance for TNF-α was performed in 450nm and corrected with 540nm for optical 
imperfections. The results are shown as the mean ± SD for eight animals in each group. The significance of 
difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons. 
(One-way ANOVA, ****= p< 0.0001, ***= p< 0.001 and ** =p< 0.01). 
 
5.2.6.2 Pancreatic and lung IL-6 production in caerulein-induced acute pancreatitis 
following delivery of in vivo siRNA 
Treatment with caerulein and siRNA had a significant effect on the levels of pancreatic IL-
6 (F (2, 15) = 13.92 p<0.0012) (One-way ANOVA, p<0.0004) (Figure 5-7 A). Increased 
levels of pancreatic IL-6 in the caerulein-induced acute pancreatitis mice (mean 138.4 ± 
45.50SD) were observed compared to the saline group (mean 56.78 ± 12.08SD). Pre-
treatment with siRNA had an inhibitory effect on the levels of IL-6 (mean 60.59 ± 22.99SD) 
compared to the caerulein-induced acute pancreatitis group (Figure 5-7 A). Caerulein and 
siRNA treatment had a significant effect on the levels of lung IL-6 (F (2, 15) = 33.99 
p<0.0001) (One-way ANOVA, p<0.0001) (Figure 5-7 B). Lung IL-6 levels in the caerulein-
induced acute pancreatitis mice were increased (mean 40.33 ± 5.36SD) compared to the 
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mice that received only saline (mean 17.92 ± 5.591SD) (Figure 5-7 B). Silencing CSE gene 
with in vivo siRNA targeting CSE targeting showed an inhibitory effect on the levels of IL-
6 (mean 25.71 ± 3.19SD) compared to the caerulein group (Figure 5-7 B). 
 
Figure 5-7. SiRNA treatment attenuated caerulein-induced increase IL-6 levels in the pancreas and lungs. 
Samples were collected from the pancreas and lung tissues from mice given 10 hourly injections of saline or 
caerulein (50 µg/kg) or caerulein pre-treated with single dose of siRNA (7mg/kg/day) 24h prior to caerulein 
treatment. The tissue samples were homogenised and the supernatant was used for ELISA. The absorbance for 
IL-6 was performed at 450nm and corrected with 540nm for optical imperfections. The results are shown as 
the mean ± SD for six animals in each group. The significance of difference among groups was evaluated by 
ANOVA with a post hoc Tukey’s test for multiple comparisons. (One-way ANOVA, ****= p< 0.0001, ***= 
p< 0.001 and ** =p< 0.01). 
 
5.2.6.3 Pancreatic and lung MCP-1 production in caerulein-induced acute 
pancreatitis following delivery of in vivo siRNA 
Caerulein and siRNA treatment had a significant effect on the levels of pancreatic MCP-1 
(F (2, 15) = 25.76 p<0.0001) (One-way ANOVA, p<0.0001) (Figure 5-8 A). There was a 
significant increase in the levels of pancreatic MCP-1 in caerulein-induced acute pancreatitis 
mice (mean 311.30 ± 98.57SD) compared to the saline control group (mean 42.88 ± 
27.64SD) (Figure 5-8 A). Administration of siRNA against H2S synthesising CSE had an 
inhibitory effect on the pancreatic levels of MCP-1 (mean 171.8 ± 53.14SD) compared to 
caerulein-treated mice (Figure 5-8 A).  
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There was also significant effect on the lung MCP-1 levels treated with caerulein and siRNA 
(F (2, 15) = 18.54 p<0.0001) (One-way ANOVA, p<0.0001) (Figure 5-8 B). Caerulein-
induced acute pancreatitis increased the levels of lung MCP-1 (mean 214.5 ± 79.00SD) 
compared to the saline control group (mean 27.33 ± 12.25SD). Silencing H2S synthesising 
CSE with siRNA resulted in reduced levels of MCP-1 (mean 98.69 ± 47.09SD) compared 
to the caerulein-treated mice (Figure 5-8 B). 
 
 
Figure 5-8. SiRNA treatment attenuated caerulein-induced increase in the MCP-1 production in the pancreas 
and lungs. The samples were collected from the pancreas and lung tissues from mice given 10 hourly injections 
of saline or caerulein (50 µg/kg) or caerulein pre-treated with single dose of siRNA (7mg/kg/day) 24h prior to 
caerulein treatment. The tissue samples were homogenised and the supernatant was used for the ELISA. The 
absorbance for MCP-1 was performed at 450nm and corrected with 540nm for optical imperfections. Results 
are shown as the mean ± SD for six animals in each group. The significance of difference among groups was 
evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons. (One-way ANOVA, ****= p< 
0.0001, ***= p< 0.001, ** =p< 0.01 and *= p<0.5). 
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5.2.6.4 Pancreatic and lung MIP-2 production in caerulein-induced acute pancreatitis 
following delivery of in vivo siRNA 
Caerulein and siRNA treatment had a significant effect on the levels of pancreatic MIP-2 (F 
(2, 15) = 28.31 p<0.0001) (One-way ANOVA, p<0.0001) (Figure 5-9 A). There was a 
significant increase in the levels of pancreatic MIP-2 in caerulein-induced acute pancreatitis 
mice (mean 6.036 ± 1.783SD) compared to the saline control group (mean 1.935 ± 
0.8579SD) (Figure 5-9 A). Administration of siRNA against H2S synthesising CSE had an 
inhibitory effect on the levels of MIP-2 (mean 1.270 ± 0.8649SD) compared to caerulein 
treated mice (Figure 5-9 A). 
There was also significant effect on the lung MIP-2 levels in mice treated with caerulein and 
siRNA (F (2, 15) = 37.59 p<0.0001) (One-way ANOVA, p<0.0001) (Figure 5-10 B). 
Caerulein-induced acute pancreatitis increased the levels of lung MIP-2 (mean 1.73 ± 
0.31SD) compared to the saline control group (0.59 ± 0.17SD). Silencing H2S synthesising 
CSE with siRNA resulted in reduced levels of MIP-2 (mean 1.14 ± 0.17SD) compared to 
the caerulein-treated mice (Figure 5-9 B). 
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Figure 5-9. SiRNA treatment attenuated caerulein-induced increase in the MIP-2 production in the pancreas 
and lungs. Tissues were collected from the pancreas and lung tissues from mice given 10 hourly injections of 
saline or caerulein (50 µg/kg) or caerulein pre-treated with single dose of siRNA (7mg/kg/day) 24h prior to 
caerulein treatment. Tissue samples were homogenised and the supernatant was used for an ELISA assay. The 
absorbance for MIP-2 was performed at 450nm and corrected with 540nm for optical imperfections. The 
results are shown as the mean ± SD for six animals in each group. The significance of difference among groups 
was evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons.  (One-way ANOVA, ****= 
p< 0.0001 and ** =p< 0.01). 
 
5.2.7 Histopathological changes of pancreas and Lung in acute pancreatitis induced 
mice 
Histological analysis revealed oedema formation and increased number of leukocyte 
infiltration in the pancreas following induction of acute pancreatitis with caerulein (Figure 
5-10 B). Silencing the CSE gene using siRNA resulted in a significant decrease of 
infiltrating leukocytes in the pancreas (Figure 5-10 C). Infiltration of leukocytes in lungs 
and alveolar thickening was observed mice with caerulein-induced acute pancreatitis (Figure 
5-10 E). Silencing CSE with siRNA reduced inflammation in the lungs with reduced 
alvelorar thickening and leukocyte infiltration (Figure 5-10 F).  




Figure 5-10. Histological changes of the pancreas and lungs after induction of acute pancreatitis with caerulein. 
Representative images using haematoxylin and eosin staining in pancreas and lung samples from mice 
receiving 10x1 hourly injections of saline or caerulein (50µg/kg) or caerulein (50µg/kg) pre-treated with a 
single dose of siRNA (7mg/kg/day) 24h prior to caerulein injection are shown. A (pancreas) and D (lung) 
saline treatment; B (pancreas) and E (lung): caerulein treatment; C (pancreas) and F (lung): caerulein with 
siRNA treatment; G, H, and I are magnified view for A, B, and C respectively. The scale bar is 100μm. (n=8 
for each group). Arrows indicate the infiltrated leukocytes. 
 
5.2.8 Histopathological changes of spleen after induction acute pancreatitis 
Immunohistochemical sections of the spleen using CD11b staining revealed that the 
monocyte population resides in two regions, the marginal zone and the sub-capsular red 
pulp. Upon inflammation the monocyte population was reduced in the spleen. The results 
showed a higher population of monocytes in the control group (igure 5-11 A) compared to 
acute pancreatitis group (Figure 5-11 B).  
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Figure 5-11. Histological changes of the spleen after induction of acute pancreatitis. Representative images of 
immunohistochemical staining of CD11b positive cells in the spleens from mice receiving 10x1 hourly 
injections saline or caerulein (50µg/kg) are shown. A: saline treatment; B: caerulein treatment, C and D are 
magnified view of A and B respectively. The scale bar is 100µm. Arrows indicate the monocyte populations 
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5.3 Discussion 
CD11b staining of spleen sections showed that monocytes reside in the marginal and the 
sub-capsular red pulp in the spleen in accordance with a previous report by Leuschner et al 
[101]. It was also shown that in vivo siRNA delivery into monocytes resulted in 
accumulation of these nanoparticles predominantly in the spleen two hours after tail vein 
injection [101]. The present experiments also showed a reduced number of splenic 
monocytes in caerulein-induced acute pancreatitis model compared with control group. The 
spleen is a reservoir for monocytes and these cells are deployed to inflammatory sites upon 
inflammation [345]. In the study reported by Leuschner et al [101]. They showed that 
monocytes migrated from the spleen to the heart in a mouse model of ischemic myocardium 
and this resulted in a reduced population of monocytes in the sub-capsular red pulp of the 
spleen. In an in vivo study of a rat model of acute pancreatitis, splenic atrophy has been 
reported. Splenocyte migration into the systemic circulating system was proposed as the 
mechanism for reduced weight of the spleen in this experiment [346].  
During inflammation monocytes infiltrate the lung and differentiate into macrophages. 
Caerulein administration has resulted in leukocytes infiltration in the lungs in agreement 
with a previous report (Bhatia et al. 2005), but the leukocyte infiltration was reduced in mice 
treated with siRNA. Therefore, lung tissue was used to determine the effect of in vivo siRNA 
on the expression CSE. Western blot analysis showed reduced CSE protein expression in 
lung tissue of siRNA treated mice.  
Administration of siRNA against CSE reduced pancreatic oedema and inflammatory 
leukocyte infiltration of pancreatic tissue. These findings demonstrate a protective effect of 
silencing the CSE gene with siRNA against acute pancreatitis. CSE gene deletion in mice 
(CSE knockout mice) [45] and inhibition of hydrogen sulfide production with PAG [1] 
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reduced the severity of acute pancreatitis and associated lung injury. Inhibition of hydrogen 
sulfide production with PAG has resulted in reduced pancreatic MPO activity with 
diminished pancreatic injury and leukocyte infiltration.                                           
 Severe acute pancreatitis is associated with lung injury which is characterised by the 
sequestration of neutrophils and increased MPO activity in the lung [347]. My results 
showed that administration of siRNA against CSE protected mice against pancreatitis 
associated lung injury by reduction of MPO activity and reduced leukocyte infiltration. 
These findings are in agreement with previous studies in acute pancreatitis showing that 
inhibition of H2S with PAG [1] and in CSE knockout mice has resulted in reduced lung 
MPO activity, reduced alveolar thickening and reduced leukocyte infiltration [45].   
The results presented also demonstrated that siRNA against CSE attenuated 
hyperamylasemia in acute pancreatitis. Similar results were reported following inhibition of 
H2S with PAG [1] and in CSE knockout mice [45]. 
Inhibition of CSE gene expression by siRNA inhibited inflammation by reducing the levels 
of pro-inflammatory cytokines. In vivo silencing of CSE expression in monocytes resulted 
in reduced levels of TNF-α, IL-1β, IL-6, MIP-2 and MCP-1 in caerulein-induced acute 
pancreatitis. These findings demonstrate a pro-inflammatory role for CSE and are in 
agreement with previous findings [45]. This showed reduced levels of pro-inflammatory 
mediators in CSE knockout mice compared with wild type animals in acute pancreatitis and 
demonstrated a pro-inflammatory role for CSE. Pharmacological inhibition of H2S 
production by PAG in an animal model of acute pancreatitis resulted in reduced levels of 
MCP-1 [1, 315]. Results reported in this thesis show that inhibition of H2S synthesising CSE 
gene expression is linked to the levels of pancreatic and lung MCP-1 suggesting that siRNA 
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targeting CSE in macrophages could have anti-inflammatory potential for the treatment of 
acute pancreatitis. 
The experiments have shown that siRNA targeting CSE was successfully delivered into 
macrophages in the pancreas and lung. This resulted in a subsequent decrease in the severity 
of acute pancreatitis by reduction in the levels of pancreatic and lung MPO activity, plasma 
amylase activity, pro-inflammatory cytokines, and also evidence of diminished tissue 
damage in the pancreas and lung in caerulein-induced acute pancreatitis in mice. Silencing 
the CSE gene in macrophages leading to inhibition of H2S biosynthesis could be a 
therapeutic strategy to regulate activation of these cells in acute pancreatitis
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6 CSE expression in LPS-induced human primary macrophages and 
role of NF-κB and MAP kinase in biosynthesis of CSE in these cells 
 
6.1   Introduction 
Macrophages play a crucial role in inflammation and tissue haemostasis. LPS induces the 
production of main pro-inflammatory mediators (TNF-α, IL-1, and IL-6) in macrophages [348] 
and similar results was shown in RAW 264.7 cells. Macrophages play key roles in human and 
are involved in tissue repair, homeostasis, and immune response. Homeostatic and repair 
functions could be disrupted by constant offense which could led to involvement of 
macrophages in diseases such as obesity, fibrosis, and cancer. Therefore, macrophages are 
considered as divers set of cells that continually change their function state to new metastable 
state in response to changes in tissue physiology. Macrophages could be divided as different 
functional subsets of cells according to their origins [349]. 
Initially, activated macrophages are beneficial because of their response against invading 
pathogens, but they also cause considerable tissue damage due to toxic activity of reactive 
oxygen and nitrogen species [350]. Uncontrolled response of macrophages could be pathogenic 
and cause disease progression which is seen in chronic inflammatory and autoimmune diseases 
[351, 352]. To neutralise tissue damaging potential of activated macrophages, these cells 
undergo apoptosis or change to anti-inflammatory phenotype to reduce the pro-inflammatory 
response of these cells that potentially could be tissue damaging [353]. The mechanisms that 
control the alteration of inflammatory macrophages into an anti-inflammatory cell or 
suppressive macrophages back into a pro-inflammatory phenotype plays a key role in the 
development and resolving of many chronic diseases [349].  
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The liver and pancreas are metabolic organs in human composed of parenchymal and stromal 
cells, including macrophages that maintain metabolic homeostasis [354]. In response to 
bacterial infection, macrophages become activated and secrete pro-inflammatory cytokines, 
such as TNF-α, IL-6 and IL-1β, which communally stimulate peripheral insulin resistance to 
decreased nutrient storage [355, 356]. 
H2S is a novel endogenous signalling gasotransmitter [162] generated from l-cysteine by the 
activity of CSE in macrophages [182]. Accumulating data have indicated that H2S is associated 
in various physiological and pathological processes [357]. An in vitro study showed that H2S 
treatment of human macrophage cell line, U 937, has stimulatory effect on the activation and 
secretion of pro-inflammatory cytokines by these cells via ERK- NF-κB pathways [237]. H2S 
has been shown to increase macrophage infiltration to infracted myocardium in mice [358].  
NF-κB plays a key role as a central transcription factor regulating the transcription of many 
inflammatory mediators and adhesion molecules. NF-κB has been the target for developing 
novel treatments for inflammatory diseases because of its important role in immune response 
[359-361]. NF-κB exists in the cytoplasm and is bound to its inhibitory protein κB (IkB). 
Following activation, NF-κB dissociates from IkB and translocates into the nucleus and binds 
to 10-bp sequences in the regulatory regions of several inflammatory genes, up-regulating their 
transcription [362, 363]. Bay 11-7082 is a selective and irreversible inhibitor of IκBα 
phosphorylation, which inhibits NF-κB activation [364]. 
The three MAPKs family are important modulators of inflammatory responses. In 
inflammation, the MAPK cascade is activated through phosphorylation of p38, ERK, and JNK. 
The inflammatory response, including cytokines and their genes, mediate MAPKS activation 
by signal-transduction pathway via translocation of NF-κB from the cytoplasm to the nucleus. 
Consequently, inhibition of MAPKs pathways protects against inflammatory responses [365-
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367]. Previous studies showed that MAPKs, the upstream regulators of NF-κB, acted as a key 
role in LPS-induced inflammatory mediators released by macrophages [368, 369]. Regulation 
of MAPK family is considered as a major target to understand the mechanism of NF-κB 
signalling with treatments [370, 371]. PD 98059 is generally used to inhibit the ERK pathway. 
Inhibition of MEK by PD 98059 inhibited activation of MAPK and subsequent 
phosphorylation of MAPK substrates both in vitro and in vivo [372, 373]. The set of 
experiments in this section examined the expression of CSE in macrophages isolated from 
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6.1.1 Objectives   
 
 To determine CSE gene and protein expression in human primary macrophages. 
 To demonstrate the up-regulation of the CSE gene in human primary macrophages 
following activation with LPS. 
 To examine the effect of the inhibition of NF-κB on CSE gene and protein expression 
in LPS-treated human macrophages. 
 To determine the role of MAPKs in the expression of CSE gene and protein in LPS-
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6.2 Results 
6.2.1 CSE gene expression in human primary macrophages  
LPS treatment of human primary macrophages showed that there was no CSE protein 
expression in these cells after 24h treatment with LPS. Therefore human primary macrophages 
were treated for 48h with LPS in these experiments. To assess the effect of activation through 
LPS treatment on CSE mRNA levels, 48 hours after treating the cells with 1µg/ml LPS the 
RNA was extracted, converted to cDNA and amplified using PCR. Following electrophoresis 
there was a single band for the CSE gene present (Figure 6-1). 
 
Figure 6-1. RT-PCR analyses for CSE gene in human primary macrophages. Cells were treated with 1µg/ml LPS 
for 48h. Total RNA was extracted from untreated and LPS treated cells and converted to cDNA. The house 
keeping gene is r18S in this experiment. 
 
6.2.2 Quantitative PCR for CSE expression in LPS-induced human primary 
macrophages  
Quantitative PCR was then conducted to compare the levels of expression of the CSE gene in 
the absence or presence of LPS. The results showed that treatment of macrophages (1µ/ml) for 
48 hours increased the expression of CSE mRNA four-fold compared to untreated (control) 
cells (Figure 6-2). 
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Figure 6-2. QPCR analysis in LPS-treated human primary macrophages. Cells were seeded in 12 well plates and 
treated with 1µg/ml LPS for 24h. Total RNA extracted from untreated and LPS-treated cells and converted to 
cDNA. CSE mRNA expression was normalised with r18S expression and expressed as fold increased over control 
cells. The level of mRNA expression for CSE in LPS-treated cells was higher than untreated cells. The results are 
shown as the mean ± SD. (t-test, **=p<0.01 compared to control) (n=4). 
 
6.2.3 CSE protein expressionin LPS-induced human primary macrophages 
Human primary macrophages were provided by Associate Professor Steven Gieseg’s 
laboratory and were seeded in 12 well plates as described in chapter 2 (2.2.1.3). Cells were 
treated with 1 µg/ml LPS for 48 hours. Protein was then extracted using a lysis buffer. A DC 
protein assay was then used to calculate the amount of protein in the homogenate. Equal 
amounts of the protein were loaded onto a SDS-PAGE gel (12%). The western blot was then 
probed with the antibody against CSE and visualized using a UVITEC chemidoc.  From this a 
single protein band of approximately 43 kDa corresponding to CSE protein was found (t-test 
P<0.0001, Figure 6-3).   
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Figure 6-3. Western blot (A, B, and C) and densitometry analysis (D) of CSE expression in untreated (control) 
and LPS treated human primary macrophages. Cells were treated with LPS for 48h and the whole lysate was 
analysed with western blot. CSE protein expression was normalised with GAPDH (housekeeping protein and 
expressed as fold increase over control cells. CSE protein levels, with LPS treated cells had higher levels of CSE 
protein. The results are shown as the means ± SD. (t-test, ****= p<0.0001 compared to control). (n=3).  
 
6.2.4 Effect of treatment of Bay 11-7082, a specific NF-κB inhibitor, on CSE expression 
in LPS-induced human primary macrophages 
The compound Bay 11-7082 has been reported to inhibit NF-κB activity in macrophages, at a 
level of 30µM of Bay 11-7082 [314].  In this experiment a range of doses of Bay 11-7082 (10 
µM, 20 µM, and 30 µM) was used. The results shows that 30 µM Bay 11-7082 inhibited NF-
κB activity and down-regulated CSE expression significantly (Figure 6-4). 
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Figure 6-4. Inhibition effect of different doses of Bay 11-7082 on CSE mRNA expression in human primary 
macrophages. The control group received DMSO, the LPS group was incubated with 1µg/L LPS 48h prior to 
qPCR and the LPS + Bay 11-7082  group received 10, 20 and 30 µM Bay 11-7082, a specific inhibitor of NF-κB 
50min prior to LPS treatment. Total RNA was extracted and converted to cDNA to perform qPCR. CSE mRNA 
expression was normalised with r18S (housekeeping gene) and expressed as fold control. The results showed that 
inhibition of NF-κB with 30 µM Bay 11-7082 significantly reduced CSE expression in macrophages. The results 
are shown as the mean ± SD. The significance of difference among groups was evaluated by ANOVA with a post 
hoc Tukey’s test for multiple comparisons. (One-way ANOVA, **= p< 0.01 and * =p< 0.05). (n=3). 
 
 
Real time quantitative RT-PCR was performed to quantify CSE transcription in LPS-induced 
human primary macrophages. LPS and Bay 11-7082 had a significant effect on CSE expression 
in human primary macrophages (F (2, 6) =12.28, p=0.0076) (Figure 6-5). LPS treatment 48 
hours prior to qPCR resulted in a significantly higher level of CSE expression with levels 4.083 
(1.052 SD) fold higher than control (One-way ANOVA, p<0.01) (Figure 6-5). Inhibition of 
NF-κB using a generally applied inhibitor, Bay 11-7082, inhibited the LPS-induced up-
regulation of CSE expression with levels only 1.900 (0.7955 SD) fold higher than control (One-
way ANOVA, p<0.05) (Figure 6-5).   
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Figure 6-5. The effects of LPS and Bay 11-7082 on CSE mRNA expression in human primary macrophages. The 
control group received DMSO, the LPS group was incubated with 1µg/L LPS 48h prior to qPCR and the LPS + 
Bay 11-7082 group received 30 µM Bay 11-7082, a specific inhibitor of NF-κB 50min prior to LPS treatment. 
Total RNA was extracted and converted to cDNA to perform qPCR. CSE mRNA expression was normalised with 
r18S (housekeeping gene) and expressed as fold control. Inhibition of NF-κB significantly reduced CSE 
expression in macrophages. Results are shown as the mean ± SD. The significance of difference among groups 
was evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons. (One-way ANOVA, **= p< 
0.01 and * =p< 0.05). (n=3). 
 
 
To examine the effect of inhibition of NF-κB activity on CSE protein expression, western blot 
analysis was performed. A single protein band of approximately 43kDa corresponding to CSE 
protein was observed. Human macrophages treated with LPS expressed higher level of protein 
(Figure 6-3). Inhibition of the NF-κB pathway had inhibitory effects on CSE protein expression 
(Figure 6-6).  
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Figure 6-6. Western blot (A, B, and C) and densitometry analysis (D) of CSE protein expression by human primary 
macrophages. LPS-treated cells were incubated with and without NF-κB inhibitor for 48 h. Control cells received 
DMSO. LPS + Bay 11-7082 group treated with Bay 11-7082 for 50min prior to treatment with LPS for 48 h. Total 
cell lysates were examined by western blot with anti-CSE antibody to detect CSE expression. The histograms 
represent the optical density of CSE protein expression relative to GAPDH expressed as control fold increase. 
The significance of difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for multiple 
comparisons. The results are shown as the mean ± SD. (One-way ANOVA, ****= p< 0.0001 and ** =p< 0.01). 
(n=3). 
 
6.2.5 Effect of PF 98059, a specific ERK pathway inhibitor, on the expression of CSE in 
human primary macrophages 
PD 98059 is a selective inhibitor of MAP kinases (also known as MAP/ERK kinase). Different 
doses of PD 98059 (10 µM, 20 µM, 30 µM, 50 µM) were used and the results showed that 50 
µM was the most effective dose needed to inhibit ERK phosphorylation in human primary 
macrophages (Figure 6-7). Therefore this dose of PD 98050 was used in this experiment.  
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Figure 6-7. The effects of LPS and PD98059 on CSE mRNA expression in human primary macrophages. The 
control group received DMSO, the LPS group was incubated with 1µg/L LPS 48h prior to qPCR and the LPS + 
PD 98059 group received 10, 20, 30, and 50  µM PD 98059, a specific inhibitor of ERK 50min prior to LPS 
treatment. Total RNA was extracted and converted to cDNA to perform qPCR. CSE mRNA expression was 
normalised with r18S (housekeeping gene) and expressed as fold control. Inhibition of ERK with 50 µM PD 
significantly reduced CSE expression in macrophages. The results are shown as the mean ± SD. The significance 
of difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons. 
(One-way ANOVA, **= p< 0.01 and*= p<0.05). (n=3). 
 
 LPS treatment 48 hours prior to qPCR resulted in a significantly higher level of CSE 
expression with levels 5.2 (2.0 SD) fold higher than control (One-way ANOVA, p<0.05) 
(Figure 6-8). Inhibition of ERK using PD 98059, inhibited the LPS-induced up-regulation of 
CSE expression with levels only 1 (1.01 SD) fold higher than control (One-way ANOVA, 
p<0.05) (Figure 6-8).   
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Figure 6-8. The effects of LPS and PD 98059 on CSE mRNA expression in human primary macrophages. The 
control group received DMSO, the LPS group was incubated with 1µg/L LPS 48h prior to qPCR and the LPS + 
PD 98059 group received 50µM PD 98059, a specific inhibitor of ERK 50 minutes prior to LPS treatment. Total 
RNA was extracted and converted to cDNA to perform qPCR. CSE mRNA expression was normalised with r18S 
(housekeeping gene) and expressed as fold control. The significance of difference among groups was evaluated 
by ANOVA with a post hoc Tukey’s test for multiple comparisons. theesults are shown as the mean ± SD. (One-
way ANOVA, *= p< 0. 05). (n=3).  
 
 
Western blot analysis show that cells treated with LPS expressed higher levels of protein 
compared to control group. Inhibition of the ERK pathway had inhibitory effects on CSE 
protein expression in LPS-induced macrophages (Figure 6-9).  
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Figure 6-9. Western blot (A, B, and C) and densitometry analysis (D) of CSE protein expression by human primary 
macrophages pre-treated with PD 98059. Control cells received DMSO and LPS treated cells were incubated with 
LPS for 48h. LPS+ PD 98059 group treated with PD 98059 for 5min before treatment with LPS for 48 h. the total 
cell lysates were examined by western blot with anti-CSE antibody to detect CSE expression. The histograms 
represent the optical density of CSE protein expression relative to GAPDH expressed as control fold increase. 
The significance of difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for multiple 
comparisons. The results are shown as the mean ± SD. (One-way ANOVA, **= p< 0.01). (n=3). 
 
6.2.6 Effect of SP 600125 and SB 203580 a specific JNK and p38 pathways inhibitors, 
on the expression of CSE in human primary macrophages 
SP 600125 and SB 203580 are selective inhibitors of JNK and p38, respectively. Different 
doses of SP 600125 (20 µM, 30 µM) and a range of doses of SB 203580 (10-20 µM) were used 
to inhibit JNK and p38 phosphorylation in human primary macrophages. The results showed 
that inhibition of phosphorylation of these protein did not block CSE expression in LPS-
induced human primary macrophages (Figure 5-10). 
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Figure 6-10. The effects of LPS, SP 600125 and SB 203580 on CSE mRNA expression in human primary 
macrophages. (A) The control group received DMSO, the cells of LPS group were incubated with 1µg/L LPS 48h 
prior to qPCR and the LPS + SP 600125 group received 20 and 30 µM SP 600125, a specific inhibitor of JNK 
50min prior to LPS treatment. (B) The control group received DMSO, the LPS group was incubated with 1µg/L 
LPS 48h prior to qPCR and the LPS + SB 203580 group received 10 and 20  µM SB 203580, a specific inhibitor 
of p38 50min prior to LPS treatment. Total RNA was extracted and converted to cDNA to perform qPCR. CSE 
mRNA expression was normalised with r18S (housekeeping gene) and expressed as fold control. Inhibition of 
JNK and p38 did not reduced CSE expression in macrophages. The results are shown as the mean ± SD. (One-
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6.3 Discussion  
Human primary macrophages were investigated for CSE gene and protein expression. The 
expression of CSE in human primary macrophages was also determined. Macrophages produce 
H2S by the activity of CSE and increased level of CSE gene expression and H2S production is 
reported in these cells following activation [307, 308]. H2S is an inflammatory mediator with 
an important role in normal physiology and the disease state. Heightened levels of H2S [308] 
and upgraded CSE mRNA expression [172, 308] following LPS administration have been 
shown. H2S acts as a regulatory mediator of macrophages during inflammation [165, 301, 315]. 
It has been shown previously that H2S activates NF-κB in human monocyte U937 cells via 
degradation of IkB-α [314] and Bay 11-7082 inhibits phosphorylation of IκBα selectively 
[364]. The experimental results reported in this chapter demonstrate that inhibition of NF-κB 
with Bay 11-7982, a specific NF-κB inhibitor, resulted in reduced levels of CSE gene and 
protein expression in LPS-treated human primary macrophages. Inhibition of the ERK pathway 
also confirmed an important role for MAPKs in the biosynthesis of CSE. The inhibitory effect 
of PD 98059 on ERK phosphorylation has been shown to be dose dependent and 50 µM of this 
inhibitor was reported to block ERK phosphorylation in macrophages significantly [314, 374, 
375]. The results described in this section also showed that inhibitory effect of PD 98059 is 
dose dependent and 50 µM of this compound had significant inhibitory effect on LPS-induced 
CSE expression in human primary macrophages. Reduced levels of CSE gene and protein 
levels were observed in macrophages following inhibition of ERK. This finding was in 
accordance with previous report by Yang et al, showing that over expression of CSE gene 
activates phosphorylation of ERK1/2 [151].  
It has been shown that 1-10 µM of SB 203580 and SP 600125 inhibit p38 and JNK 
phosphorylation in RAW 264.7 cells [375-377]. In contrast to these reports SP 600125 and SB 
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203580 did not show inhibitory effects on LPS-induced CSE expression in human primary 
macrophages. Therefore, LPS regulates CSE biosynthesis via ERK/NF-κB signalling pathway 
in human primary macrophages. Previously p38 was reported to be involved in CSE 
biosynthesis and H2S production in LPS-induced RAW 264.7 cells [307]. However, the results 
in this set of experiments showed that inhibition of p38 and JNK did not have inhibitory effects 
on CSE expression in macrophages.  
In conclusion, the set of experiments described in this chapter demonstrated CSE gene and 
protein expression in human primary macrophages. Further investigation of the role of 
signalling pathways in human macrophages revealed that LPS increased the levels of CSE in 
human primary macrophages via the ERK/NF-κB pathway. However, inhibition of p38 and 
JNK pathways did not reduce CSE expression in LPS-induced human primary macrophages. 
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7 General discussion  
 
7.1 Discussion and summary  
The immediate response of immune system to noxious stimuli is to attract the immune cells 
and molecules to the injured site. Macrophages are an important class of cells in the immune 
system and play a crucial role in inflammation. Macrophages produce a wide range of 
biologically active molecules that participate in both beneficial and detrimental outcomes 
in inflammation. Therefore, therapeutic interventions targeted towards macrophages and their 
products may open new avenues for treating inflammatory diseases.  
H2S is a gasotransmitter molecule produced naturally in the body with ability to permeate 
through the cell membrane freely and exert important physiological functions. H2S is produced 
by the activity of three enzymes: mainly CSE and CSB which use L-cysteine as a substrate and 
pyridoxal 5’-phosphate (PLP) as a cofactor to produce H2S, and also 3-MST, which is non-PLP 
dependent and uses 3-mercaptopyruvate a metabolite of L-cysteine as a substrate for H2S 
generation. CSE is predominantly expressed in peripheral cells while CBS is major H2S 
producing enzyme in CNS. [378, 379].  
The role of H2S in inflammation has only recently emerged, and its exact role is still not clearly 
understood. Many studies have shown that H2S acts as an inflammatory mediator [86, 199, 
339, 380] and several studies have shown the beneficial effects of H2S in cardiovascular and 
neurological disorders [340]. However, H2S has been shown to act as a pro-inflammatory 
mediator in some disease states such as sepsis [152] acute pancreatitis [1, 3, 200], hindpaw 
oedema [86] and ischaemic injury [381]. Previous reports demonstrated that inhibition of H2S 
production by PAG, could ameliorate inflammation and reduce the severity of disease such 
129 
  Chapter 7 
sepsis [2, 152], acute pancreatitis and associated lung injury [2, 315], and cisplatin-induced 
renal damage [382]. However, poor specificity of PAG as a H2S inhibitor, makes inhibition of 
H2S synthesis by siRNA silencing a more attractive method by which investigate the role of 
hydrogen sulphide in inflammation.  
The aims of this thesis were to study the effect of CSE up-regulation in macrophage activation 
and its effects on a mouse model of acute pancreatitis. LPS-induced CSE up-regulation in 
primary murine macrophages and RAW 264.7 cells was reported by Zhu et al [182]. This study 
revealed expression of CSE in macrophages but not CBS. Increased CSE expression in LPS-
induced macrophages has also resulted in a higher level of synthesized H2S in these cells [182]. 
A significantly reduced level of H2S was shown in LPS-induced macrophages following 
silencing CSE with siRNA [182], suggesting CSE was the main enzyme for H2S production in 
activated macrophages. The results presented in this thesis conclusively demonstrated 
expression of the CSE gene but not the CBS gene in RAW 264.7 cells. In vitro investigation 
in human primary macrophages also showed expression of the CSE gene in these cells. 
Increased expression of CSE was observed in LPS-induced macrophages compared to control 
cells.  
Following silencing of the CSE gene and reduced protein expression by siRNA, the production 
of pro-inflammatory cytokines like IL-6, TNF-α, IL-1β and MCP-1 in LPS-induced 
macrophages was reduced. CSE biosynthesis and H2S production is regulated by NF-κB in 
macrophages [307]. To determine the mechanism pertaining to the reduced levels of CSE gene 
and protein expression and reduced levels of inflammatory mediators, the effects of siRNA on 
NF-κB/ERK pathway were investigated. The results revealed that CSE targeting by siRNA 
acted via the NF-κB/ERK pathway. LPS-induced macrophages showed higher levels of NF-
κB activity compared to inactivated cells while silencing CSE with siRNA in macrophages 
resulted in reduced levels of NF-κB/ERK activity.  
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The findings presented in this thesis showed increased levels of CSE in a mouse model of acute 
pancreatitis and associated lung injury suggesting a pro-inflammatory role for CSE in 
macrophages. To determine the role of H2S synthesising CSE in macrophages, siRNA against 
CSE was administrated via tail vein injection. The in vivo bio-distribution study of siRNA 
using fluorescent labelled siRNA confirmed intracellular transference of siRNA in infiltrated 
leukocytes in the pancreas and lung of caerulein-induced acute pancreatitis.  
Following induction of acute pancreatitis with caerulein, higher levels of pro-inflammatory 
cytokines, increased leukocyte infiltration in the pancreas and lung tissues, pancreatic oedema,  
increased plasma activity and enhanced pancreatic and lung MPO activity were observed in 
mice. Importantly, silencing CSE in macrophages reduced several surrogate markers of 
severity of acute pancreatitis in mice.  Mice that received siRNA against CSE before the 
induction of acute pancreatitis showed reduced levels of pro-inflammatory cytokines, 
pancreatic and lung MPO activity and plasma amylase activity. The histological study 
performed on pancreas and lung and showed reduced infiltration of leukocytes in these tissues 
suggesting that the disease process had been attenuated and that CSE silencing by siRNA had 
protective effects.   
The spleen is known as a reservoir for macrophages [345] and during inflammation these cells 
leave spleen and migrate to the site of inflammation and where they act as pro-inflammatory 
cells [101]. The results presented also demonstrated that the spleen functions as a pool for 
monocytes. However, following induction of acute pancreatitis, these cells leave the spleen. 
Histological staining of the spleen showed a reduced population of the monocytes presented in 
the spleen of mice with induced acute pancreatitis compared with the control group. The 
summary of this thesis was shown in figure 7-1. 
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7.2 Limitations of the studies and future directions 
The results of this studies reported in this thesis have demonstrated a pro-inflammatory role for 
CSE in vitro and a mouse model of acute pancreatitis. Silencing the CSE gene in macrophages 
with siRNA attenuated the inflammatory activity of these cells in acute pancreatitis in a mouse 
model. In addition it has been shown that LPS regulates CSE biosynthesis via ERK/NF-κB 
signalling pathway in human primary macrophages creating a direct link to human disease and 
raising the possibility of modulating this pathway as a therapeutic intervention.   
However these experiments have several limitations. Firstly, the experiments were designed to 
ensure that there was a maximum inhibition of the expression of CSE genes siRNA before the 
induction of acute pancreatitis. It would be important to know whether the siRNA injected after 
the onset of pancreatitis attenuated the inflammatory response, and how long a therapeutic 
window might be.  
Secondly, the endpoints measured in these experiments were essentially biochemical in nature, 
although the amount of oedema and degree of inflammatory infiltrate were estimated in the 
mouse experimental model. It would be useful to conduct experiments in more severe disease 
with a hard clinical endpoint such as survival, given that acute pancreatitis has a high mortality 
in humans. If mortality was reduced, in mice when siRNA was administered after the onset of 
acute pancreatitis this would provide powerful evidence of the central role played by H2S in 
the pathogenesis of this condition and support investigation of siRNA as a therapeutic option. 
Similar experiments could be performed with pharmacological agents that modify the 
ERK/NF-κB signalling pathway in this model. 
Thirdly, the experiments were conducted using caerulein to induce pancreatitis. It is possible 
that the effects observed following siRNA are in some way limited to this model, although this 
seems unlikely given the central role of the macrophage in the immune response. The finding 
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of similar results in another model of pancreatitis, especially one that more closely mimics 
gallstone pancreatitis, would be a value as this is the major cause of human pancreatitis.  
A further limitation is that the experiments have been conducted only in a pancreatitis model. 
There are good reasons to think that the results will be relevant in sepsis. H2S has also been 
shown to act as a pro-inflammatory mediator in sepsis so that silencing of CSE in macrophages 
could reduce the levels of the pro-inflammatory mediators generally and this might attenuate 
the severity of sepsis.  
H2S measurement could be the fifth limitation of this study. There is only one report by Zhu et 
al (2010) [182] that shows macrophage H2S synthesizing ability in real-time using a 
miniaturized H2S micro-respiration sensor under saturating levels of L-cysteine and PLP which 
increased following treatment with LPS. Direct measurement of H2S in macrophages would 
provide further proof of the central role of H2S in the control of inflammatory system.  
It is important to place any consideration of an intervention in sepsis in context. The host 
immune response has developed to protect the host over countless years of evolutionary 
history. Attempts to modify this may well have unforeseen consequences so it is important to 
take a cautious step-wise approach and define the circumstances in which the immune response 
is responsible for harm to the host.  Because of this it would be worth considering conditions 
in which immune hyper-responsiveness is well recognised and known to be improved with 
agents that modify the immune response. These might include chronic inflammatory arthritis. 
Further studies on the role of spleen and the splenic monocytes in acute pancreatitis by tracking 
these cells will help in understanding the mechanisms of monocyte mobilization and the precise 
role of spleen in acute pancreatitis. Reducing the recruitment of monocytes to the site of 
inflammation might offer a further possibility for modifying the inflammatory response.  
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7.3 Conclusion  
This study demonstrated that macrophages contributed in the severity of acute pancreatitis via 
activity of CSE gene. Silencing CSE with siRNA demonstrated reduced inflammatory activity 
in these cells. Macrophages play an important role in inflammation and silencing H2S 
synthesising CSE with siRNA attenuated the severity in acute pancreatitis as shown by reduced 
inflammatory mediator production in the pancreas and lung and reduced pancreatic and lung 
MPO activity. In addition the H2S system is central to human monocyte function thus 
demonstrating a clear link of the results to human disease. These results are consistent with 
previous reports and make a substantial contribution to understanding the role of monocytes in 
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Figure 7-1. Summary of the project. CSE expression was determined in RAW 264.7 cells and human primary 
macrophages. Silencing CSE in RAW 264.7 cells showed that CSE activates murine macrophages via ERK/NF-
κB pathways. Inhibiting the signalling pathway in human macrophages showed that LPS regulates CSE 
synthesises through ERK/NF-κB pathways. To investigate the role of CSE in vivo, siRNA was used in a mouse 
model of acute pancreatitis. Inhibition of CSE expression with siRNA in macrophages showed protected effect 
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